,Article,Date,Symbol,Time,Title,Url
0,"  Feb 11 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:** Specialty pharmaceuticals company Mallinckrodt Plc  said it would buy pain drug maker Cadence Pharmaceuticals Inc for about $1.3 billion to expand in the hospital market, where Cadence's products are widely used.** German insurer Allianz took an 8.33 percent stake in Bayern Munich football club for 110 million euros ($150 million) as part of a deal to help the club pay down debts on its stadium and to sponsor a youth academy.** Directors of Spain's largest cable operator, Ono, agreed to push ahead with their plan to list the company on the stock market and deferred a takeover approach from Britain's Vodafone , a source said. ** Swiss food group Nestle is selling an 8 percent stake in L'Oreal to the French cosmetics firm for 6.5 billion euros, loosening their 40-year partnership and allowing both firms to boost earnings per share.** Greece's Alpha Bank is in talks to acquire part of Citibank's local retail banking operations, financial daily Imerisia reported. ** Vodafone Group Plc could have the capacity to spend $30 billion to $40 billion on acquisitions in the coming years and no deal should be too big if it makes strategic sense, Chief Executive Vittorio Colao said on Monday.** Etihad Airways is holding talks with Alitalia's banks in Rome this week about buying a stake in the troubled Italian carrier, the chief executive of the Abu Dhabi-based airline said. ** Viber Media denied a media report that the popular instant messaging application is in talks to be acquired by an Asian company. Israel's Calcalist financial newspaper reported that Viber was in talks to be acquired by a leading instant messaging company from Asia for $300 million-$400 million.** British holiday operator Thomas Cook said it agreed to sell a flight distribution business for 45 million pounds ($74 million) as part of its ongoing disposal program.** Norwegian insurer Gjensidige said it planned to cut its stake in SR Bank, in a transaction that would be worth up to 1.67 billion crowns ($273.2 million) at the current share price. Gjensidige hopes to sell at least 14 million shares and may sell all its 26.48 million-strong holding, corresponding to a 10.4 percent stake.** Private equity firm Warburg Pincus LLC said it had invested $32 million in Specialists On Call Inc, a provider of specialty physician services via video conferencing that seeks to address the shortage of on-call coverage.",2014-02-11,MNK,"Tue Feb 11, 2014 | 4:06pm EST",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0LG2EV20140211?type=companyNews
1,"  * All 10 S&P sectors rally after Yellen statement* House Republicans aim to pass debt limit bill* Sprint and CVS climb after results, Dean Foods down* Indexes up: Dow 1.2 pct, S&P 1 pct, Nasdaq 1 pctBy Ryan VlastelicaNEW YORK, Feb 11 U.S. stocks rose 1 percent in a broad rally on Tuesday, with investors relieved the Federal Reserve wouldn't make any changes to its schedule for trimming its market-friendly stimulus.All 10 S&P sectors rose on the day, with most climbing more than 1 percent. The benchmark index is now 1.6 percent away from its record closing high, recovering much of its recent weakness, which took the index down as much as 6 percent.In her first public comments as Fed chief, Chair Janet Yellen emphasized continuity in the central bank's policy strategy of cutting asset purchases by $10 billion a month, saying she strongly supports the approach of her predecessor, Ben Bernanke. Yellen also said that while the unemployment rate has fallen recently, labor market conditions needed to improve further.""Nothing unexpected was said, but the market is very encouraged to hear it confirmed that the policy of being accommodative will continue,"" said Weyman Gong, chief investment strategist at Signature in Norfolk, Virginia.The policies have been credited with fueling the market's steep gains in 2013, and they are expected to keep a floor under equity prices for as long as they continue.The Fed first announced a slowing in the bond-buying program in December, followed by another one in January. Had that pace been slowed, it may have raised concerns that the economy was still not strong enough to grow on its own. In other positive news, Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority, removing a potential market headwind.The Dow Jones industrial average was up 192.24 points, or 1.22 percent, at 15,994.03. The Standard & Poor's 500 Index was up 18.58 points, or 1.03 percent, at 1,818.42. The Nasdaq Composite Index was up 40.85 points, or 0.98 percent, at 4,189.03.The S&P 500 rose above its 50-day moving average for the first time since January 24, a technical resistance level that could fuel further gains if convincingly held. ""The market's valuation is at a high level, probably a little too high,"" said Gong, who helps oversee $3 billion in assets. ""Our economy is growing modestly, but we don't expect earnings will continue to expand at their current pace.""Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 2.5 percent to $7.88.CVS Caremark Corp rose 2.6 percent to $68.66 after the company posted higher quarterly profit as it processed more prescriptions.Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.On the downside, both Dean Foods Co and ConAgra Foods  slumped after giving weak outlooks. Dean warned of a first-quarter loss while ConAgra cut its full-year outlook. Shares of Dean slumped 8.2 percent to $13.96 while ConAgra lost 6.5 percent to $29.02.Infloblox Inc plunged 48 percent to $17.28 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 10.2 percent to $65.35.",2014-02-11,MNK,"Tue Feb 11, 2014 | 1:40pm EST",US STOCKS-Wall St up 1 pct as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG1KM20140211?type=companyNews
2,"  * Yellen statement yields no surprises* House Republicans aim to pass debt limit bill* Sprint, CVS climb after results* Indexes up: Dow 0.85 pct, S&P 0.75 pct, Nasdaq 0.62 pctBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks rose on Tuesday after new Federal Reserve Chair Janet Yellen reinforced the central bank's plan to trim its market-friendly stimulus, while also noting labor market conditions needed to improve. In her first public comments as Fed chief, Yellen emphasized continuity in the Fed's policy strategy, saying she strongly supports the approach of her predecessor, Ben Bernanke.""They are apparently loving what Janet Yellen has to say which is really, 'hold the course steady, here is what I am.'  She is not any different than what they expected her to be,"" said Ken Polcari, Director of the NYSE floor division at O'Neil Securities in New York.The gains helped push the S&P 500 through its 50-day moving average for the first time since January 24, a technical resistance level which could fuel further gains if it's is convincingly held.""They challenged the 50-day moving average, now it depends if we hold up through there today, it will give them every opportunity to try to challenge the (record) high - which isn't necessarily coming in a day or two - but if we hold up through the 50-day there is a real possibility that it goes there."" The Dow Jones industrial average rose 133.67 points or 0.85 percent, to 15,935.46, the S&P 500 gained 13.44 points or 0.75 percent, to 1,813.28 and the Nasdaq Composite  added 25.71 points or 0.62 percent, to 4,173.884.The central bank has cut its bond-buying program by $10 billion at each of its last two meetings, reducing the monthly purchases to $65 billion.Stocks also saw a potential headwind removed when Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority. Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 2.5 percent to $7.88.CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 2.6 percent to $68.66.Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.ConAgra Foods lost 6.5 percent to $29.02 as one of the worst performers on the S&P 500. The maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain consumer foods brands.Infloblox Inc plunged 46.7 percent to $17.67 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 10.2 percent to $65.35.",2014-02-11,MNK,"Tue Feb 11, 2014 | 1:19pm EST",REFILE-US STOCKS-Wall St advances as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG1AL20140211?type=companyNews
3,"  * Yellen, new Fed chair, takes hot seat at Capitol* Yellen says labor market recovery far from complete* Sprint, CVS climb after results* Indexes up: Dow 0.53 pct, S&P 0.43 pct, Nasdaq 0.45 pctBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks rose on Tuesday after new Federal Reserve Chair Janet Yellen reinforced the central bank's plan to trim its market-friendly stimulus while noting the health of the labor market needed to improve.In her first public comments as Fed chief, Yellen, giving a balanced testimony to a House committee, acknowledged recent volatility in global financial markets but said it did ""not pose a substantial risk to the U.S. economic outlook,"" and that she strongly supported the policy approach of her predecessor, Ben Bernanke. Yellen's appearance before the House Financial Services Committee began at 10 a.m. (1500 GMT).""We didn't see anything, at least in the written release that would cause us any concerns,"" said Paul Mangus, head of equity research and strategy at Wells Fargo Private Bank in Charlotte, North Carolina.""Naturally the testimony is just beginning so that will be very interesting to watch, the written testimony was in many ways a continuation of what the Bernanke policies had been."" The Dow Jones industrial average rose 83.69 points or 0.53 percent, to 15,885.48, the S&P 500 gained 7.74 points or 0.43 percent, to 1,807.58 and the Nasdaq Composite  added 18.85 points or 0.45 percent, to 4,167.023.The central bank has cut its bond-buying program by $10 billion at each of its last two meetings, reducing the monthly purchases to $65 billion.Stocks also saw a potential headwind removed when Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority. Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 5.3 percent to $8.10.CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 2.2 percent to $68.40.Of 345 companies in the S&P 500 that have reported earnings through Monday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.Conagra Foods lost 7.6 percent to $28.68 as one of the worst performers on the S&P 500. The maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain consumer foods brands.Infloblox Inc plunged 48 percent to $17.22 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.2 percent to $13.97 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 11.3 percent to $66.01.",2014-02-11,MNK,"Tue Feb 11, 2014 | 10:37am EST",US STOCKS-Wall St advances as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG10B20140211?type=companyNews
4,"  Specialty pharmaceuticals company Mallinckrodt Plc said it would buy pain drug maker Cadence Pharmaceuticals Inc for about $1.3 billion to expand in the hospital market, where Cadence's products are widely used.The deal will add Cadence's Ofirmev - an intravenous acetaminophen formulation for use in pain and fever - to Mallinckrodt's portfolio of pain products.The drug, which was approved in November 2010, is expected to have generated sales of $110.5 million in 2013.Ofirmev, used in more than 2,350 U.S. hospitals, has been used to treat an estimated 6-7 million patients since its launch in January 2011, the two companies said in a statement.Mallinckrodt said on Tuesday it would pay $14 in cash per Cadence share, representing a premium of about 27 percent to Cadence's Monday close. Cadence shares were trading slightly above the offer price at $14.03 before the bell, while Mallinckrodt was up 8 percent.""Ofirmev's growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients,"" Mallinckrodt CEO Mark Trudeau said in a statement. ""The product will be an outstanding addition to the brands component of Mallinckrodt's specialty pharmaceutical segment.""Dublin-based Mallinckrodt, spun off from Covidien Plc last July, makes drugs for pain management, cerebral or spinal spasticity, inflammatory diseases and depression. It also makes generic drugs and active pharmaceutical ingredients. Mallinckrodt said it received debt financing commitments from affiliates of Deutsche Bank Securities. The commitments, along with cash on hand, are expected to fund the deal, it said.Mallinckrodt was advised by Deutsche Bank Securities and its legal advisers were Wachtell, Lipton, Rosen & Katz in the United States and Arthur Cox in Ireland.San Diego, California-based Cadence was advised by Lazard and Centerview Partners, and its legal advisor was Latham & Watkins LLP.(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)",2014-02-11,MNK,"Tue Feb 11, 2014 | 9:22am EST",Mallinckrodt adds pain drug with $1.3 billion Cadence deal,http://www.reuters.com//article/us-cadence-offer-idUSBREA1A15A20140211?type=companyNews
5,"  * Yellen, new Fed chair, takes hot seat at Capitol* Yellen says labor market recovery far from complete* CVS climbs after results* Futures up: S&P 1.75 pts; Dow 26 pts; Nasdaq 8.5 ptsBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks were set for a slightly higher open on Tuesday after Federal Reserve Chair Janet Yellen reinforced the Fed's plan to scale back its market-friendly stimulus while noting the health of the labor market needed to improve. In her first public comments as Fed chief, Yellen, giving a balanced testimony to a House committee, acknowledged recent volatility in global financial markets but said it did ""not pose a substantial risk to the U.S. economic outlook,"" and that she strongly supported the policy approach of her predecessor, Ben Bernanke.""Obviously it's all about Yellen today,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""We are setting ourselves up for what could be a volatile session if there are any negative surprises, by that I mean if she is not as dovish as the market may be expecting."" S&P 500 e-mini futures rose 1.75 points and were slightly above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures  rose 26 points and Nasdaq 100 futures added 8.5 points.The central bank has cut its monthly bond-buying program by $10 billion at each of its last two meetings, reducing the total amount of purchases to $65 billion.Sprint Corp, the No. 3 U.S. mobile provider, reported an increase in quarterly revenue that was ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 7.2 percent to $8.24 in premarket trading. CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 1.9 percent to $68.24 in premarket trading.Of 345 companies in the S&P 500 that have reported earnings through Monday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.Conagra Foods lost 5.8 percent to $29.25 before the opening bell after the maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain key brands in its consumer foods division.Infloblox Inc plunged 42.8 percent to $18.97 in premarket trading after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 in premarket trading after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc  said for about $1.3 billion.",2014-02-11,MNK,"Tue Feb 11, 2014 | 9:15am EST",US STOCKS-Wall St to open slightly higher; Yellen testimony due,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG0M320140211?type=companyNews
6,"  Feb 11 Specialty pharmaceuticals company Mallinckrodt Plc said it would buy pain drug maker Cadence Pharmaceuticals Inc for about $1.3 billion to expand in the hospital market, where Cadence's products are widely used.The deal will add Cadence's Ofirmev - an intravenous acetaminophen formulation for use in pain and fever - to Mallinckrodt's portfolio of pain products.The drug, which was approved in November 2010, is expected to have generated sales of $110.5 million in 2013.Ofirmev, used in more than 2,350 U.S. hospitals, has been used to treat an estimated 6-7 million patients since its launch in January 2011, the two companies said in a statement. Mallinckrodt said on Tuesday it would pay $14 in cash per Cadence share, representing a premium of about 27 percent to Cadence's Monday close.Cadence shares were trading slightly above the offer price at $14.03 before the bell, while Mallinckrodt was up 8 percent. ""Ofirmev's growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients,"" Mallinckrodt CEO Mark Trudeau said in a statement.""The product will be an outstanding addition to the brands component of Mallinckrodt's specialty pharmaceutical segment."" Dublin-based Mallinckrodt, spun off from Covidien Plc  last July, makes drugs for pain management, cerebral or spinal spasticity, inflammatory diseases and depression. It also makes generic drugs and active pharmaceutical ingredients.Mallinckrodt said it received debt financing commitments from affiliates of Deutsche Bank Securities. The commitments, along with cash on hand, are expected to fund the deal, it said.Mallinckrodt was advised by Deutsche Bank Securities and its legal advisers were Wachtell, Lipton, Rosen & Katz in the United States and Arthur Cox in Ireland.San Diego, California-based Cadence was advised by Lazard and Centerview Partners, and its legal advisor was Latham & Watkins LLP.",2014-02-11,MNK,"Tue Feb 11, 2014 | 8:59am EST",UPDATE 1-Mallinckrodt adds pain drug with $1.3 bln Cadence deal,http://www.reuters.com//article/cadence-offer-idUSL3N0LG33Q20140211?type=companyNews
7,"  Specialty pharmaceuticals company Mallinckrodt Plc (MNK.N) said it would buy Cadence Pharmaceuticals Inc CADX.O for about $1.3 billion to acquire Cadence's pain drug Ofirmev.Mallinckrodt will pay $14 in cash per Cadence share, representing a premium of about 27 percent over Cadence's last close. ""Ofirmev's growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients,"" Mallinckrodt CEO Mark Trudeau said. ""The product will be an outstanding addition to the brands component of Mallinckrodt`s specialty pharmaceutical segment,"" Trudeau said in a statement. (Reporting by Esha Dey in Bangalore)",2014-02-11,MNK,"Tue Feb 11, 2014 | 7:26am EST",Mallinckrodt to buy Cadence Pharma for $1.3 billion,http://www.reuters.com//article/us-cadence-offer-mallinckrodt-idUSBREA1A0UZ20140211?type=companyNews
8,"  Feb 11 Specialty pharmaceuticals company Mallinckrodt Plc said it would buy Cadence Pharmaceuticals Inc for about $1.3 billion to acquire Cadence's pain drug Ofirmev.Mallinckrodt will pay $14 in cash per Cadence share, representing a premium of about 27 percent over Cadence's last close. ""Ofirmev's growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients,"" Mallinckrodt CEO Mark Trudeau said.  ""The product will be an outstanding addition to the brands component of Mallinckrodt`s specialty pharmaceutical segment,"" Trudeau said in a statement.",2014-02-11,MNK,"Tue Feb 11, 2014 | 7:22am EST",Mallinckrodt to buy Cadence Pharma for $1.3 bln,http://www.reuters.com//article/cadence-offer-mallinckrodt-idUSL3N0LG30H20140211?type=companyNews
9,"   By Esha Dey  Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which is set to hit sales of $1 billion this year.The acquisition is Dublin-based Mallinckrodt's second in less than two months as it pushes into the lucrative specialty drugs market, which focuses on complex and chronic diseases.Mallinckrodt's shareholders took a dim view of the deal, however, pushing the company's shares down as much as 10 percent.Questcor has been facing federal probes into its marketing practices related to Acthar and multiple accusations from short-seller Citron Research.The company's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share held, for a total value of about $86.10 per Questcor share, the companies said in a statement on Monday.Questcor's shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange.The deal - the latest in a series of acquisitions structured to take advantage of Ireland's low corporate tax rate - represents a 27 percent premium to Questcor's Friday close.Acthar is approved by the U.S. Food and Drug Administration for 19 conditions, many of which are associated with autoimmune and inflammatory diseases, including multiple sclerosis and infantile spasms.""We currently expect solid double-digit revenue growth for Acthar to continue in the future, driven by educational efforts and further expansion into indications currently on the Acthar label,"" Mallinckrodt Chief Executive Mark Trudeau said on a conference call. Almost all of Questcor's revenue comes from the drug, which had annual sales of about $760 million in 2013, an increase of about 50 percent from 2012. The company acquired the drug from Aventis for $100,000 in 2001.Questcor's stock fell to below $20 in September 2012 as U.S. government agencies, including the Securities and Exchange Commission, launched investigations into the company's marketing practices and health insurer Aetna Inc cut reimbursement for the drug. The investigations are still on.The company has also faced repeated accusations from short-seller Citron Research regarding the drug's high price and Acthar's composition.The injectable drug, a formulation of pituitary hormones extracted from pigs, is priced at about $30,000 per vial.Acthar is expected to touch $1.9 billion in sales in 2018, according to Thomson Reuters data. Originally developed as a treatment for infantile spasms, Acthar has an orphan drug exclusivity until October 15, 2017 for the indication.FAIR VALUE? The deal values Questcor at 12 times forward earnings, well below the median of 18.4 for the broader pharmaceutical industry, according to Thomson Reuters StarMine data.In the 12 months to Friday's close, Questcor's stock had risen more than 125 percent. Still, the stock trades at a strong discount to its median 10-year historical price-to-earnings ratio.Stocks of several high-growth biotechnology companies, which led a rally in the broader market in 2013, fell on Friday, making investors anxious about how much further they may fall. Barclays analyst Ying Huang said the recent selloff in biotech stocks puts more companies in the ""sweet spot,"" with a market capitalization of $1 billion to $10 billion, where potential acquirers might give them a look.Big pharmaceutical companies facing patent expirations still need to replenish pipelines, he said.Mallinckrodt, which traces its roots back to 1840 in St. Louis, Missouri, makes drugs for pain management, cerebral and spinal spasticity, inflammatory diseases and depression. It also makes generic drugs and active pharmaceutical ingredients.The company, which bought Cadence Pharmaceuticals Inc for $1.3 billion in February, had revenue of $2.2 billion in 2013.Mallinckrodt, which was spun off from Covidien Plc in July last year, said it expected the deal to add to adjusted earnings in 2014 and significantly boost adjusted profit in 2015.Mallinckrodt will fund the deal through cash on hand and debt financing from Barclays, which also advised the company. The deal is expected to be completed in the third quarter.Wachtell, Lipton, Rosen & Katz and Arthur Cox were Mallinckrodt's legal advisers in Ireland.Centerview Partners was Questcor's financial adviser, and Latham & Watkins LLP and Matheson were its legal advisers in Ireland.(Additional reporting by Susan Kelly; Editing by Kirti Pandey and Saumyadeb Chakrabarty)",2014-04-07,MNK,"Mon Apr 7, 2014 | 2:48pm EDT",Mallinckrodt to buy Questcor for lucrative MS drug,http://www.reuters.com//article/us-questcor-offer-idUSBREA360O320140407?type=companyNews
10,"  * Internet stocks tumble* Utilities, consumer staples in positive territory* Indexes down: Dow 1 pct; S&P 1.1 pct; Nasdaq 1.2 pct   (Updates to close)By Angela MoonNEW YORK, April 7 U.S. stocks fell on Monday with the S&P 500 posting its biggest three-day drop in two months, as investors bid down Internet stocks and rotated into defensive names to protect against further declines.Internet stocks were among the day's biggest decliners with Amazon.com down 1.6 percent at $317.76 and Yahoo! Inc  off 3.5 percent at $33.07. The Global X Social Media ETF which includes Groupon Inc and LinkedIn  fell 2.5 percent.The Nasdaq index posted its worst three-day decline since November 2011. But the biotechnology sector, which saw sharp declines in the past several sessions, ended higher with the Nasdaq biotech sector index up 0.5 percent at 2,367.94.Selling pressure migrated to other sectors, with only defensives such as utilities and consumer staples  in positive territory among the 10 major S&P sectors.""This type of market behavior (buyers favoring defensive names) suggests investors are turning cautious again after the big gains in stocks during the past year,"" said Gary Thayer, chief macro strategist at Wells Fargo Advisors.""We remain long-term positive on the U.S. economy and the U.S. stock market but expect increased volatility risk this spring and summer."" The CBOE Volatility index VIX, often used to gauge investor sentiment on Wall Street, jumped 11.5 percent to 15.56. The index usually moves inversely to the S&P 500.Dish Network Corp was among the top decliners on the Nasdaq 100, down 4.4 percent at $59.51.The Dow Jones industrial average fell 166.84 points or 1.02 percent, to 16,245.87, the S&P 500 lost 20.05 points or 1.08 percent, to 1,845.04 and the Nasdaq Composite  dropped 47.973 points or 1.16 percent, to 4,079.753. Pfizer Inc, down 3 percent to $31.20, added pressure to the Dow and S&P 500. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.Earnings season gets under way this week, with results due from financials JPMorgan Chase & Co and Wells Fargo & Co , as well as retailer Bed, Bath & Beyond.S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent.A lackluster first-quarter earnings season hurt by a harsh winter could spark a pullback, some analysts said, with investors more optimistic for the second quarter.Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares climbed 18.7 percent to $80.58 while Mallinckrodt dropped 2.5 percent to $60.95.About 7.5 billion shares changed hands on U.S. exchanges, above the 6.6 billion average so far this month, according to data from BATS Global Markets.   (Reporting by Angela Moon; Editing by Nick Zieminski)",2014-04-07,MNK,"Mon Apr 7, 2014 | 4:30pm EDT",US STOCKS-Wall St ends lower; S&P 500 in biggest 3-day drop since Jan,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ1IQ20140407?type=companyNews
11,"  (Adds Carrefour, Groupama ; updates Santander)April 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:** Switzerland's Holcim unveiled a deal to buy France's Lafarge to create the world's biggest cement maker, with $44 billion of annual sales, and spark a raft of asset sales worldwide to steer it through antitrust rules.** Specialty pharmaceuticals company Mallinckrodt Plc  will buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel.** India's Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd  for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co, and got Ranbaxy India-made drugs barred from the United States.** Swedish engineering group Alfa Laval said it agreed to buy Norwegian marine and offshore pumping group Frank Mohn for 13 billion Norwegian crowns ($2.17 billion) in cash to boost its operations in the offshore oil and gas sector. ** Banco Santander Brasil SA agreed to acquire Brazil card payment processor GetNet Tecnologia SA for about 1.1 billion reais ($493 million) in a step aimed at gaining market share.** Energen Corp said it would sell its natural gas utility Alabama Gas Corp (Alagasco) to Laclede Group Inc  for $1.28 billion in cash to focus on oil and gas exploration and production. Laclede will also assume about $320 million of Alagasco's debt.** The Moulin family that controls French department store Galeries Lafayette said it bought a 6.1 pct stake in Carrefour , making it the second-biggest shareholder in the French supermarket chain. ** Italy's Risanamento said it would accept an offer from former owner Luigi Zunino to buy two French properties out of nine it was planning to sell to Chelsfield/The Olayan Group if the British fund approved the deal.** Vocus Inc, a provider of cloud-based marketing and public relations software, said it would be bought by private equity firm GTCR Valor Merger Sub Inc for about $446.5 million. ** Foxconn Technology Group, Apple Inc's main contract manufacturer, is in talks with Asian private equity firm MBK Partners to buy Taiwanese cable TV company China Network Systems, a source with knowledge of the matter told Reuters.** Swiss drugmaker Roche has agreed to buy privately held U.S. diagnostics company IQuum in a deal worth up to $450 million to strengthen its molecular diagnostics business.** Etihad Airways is still negotiating commercial terms for a potential investment in Alitalia and is close to extending its partnership with Air Berlin, the chief executive of the Abu Dhabi airline said.** French insurer Groupama said it launched the sale of its entire 1.8 percent stake in Saint-Gobain, Europe's biggest supplier of construction materials.($1 = 5.99 Norwegian krones)   ($1 = 6.55 Swedish crowns)  ($1 = 0.73 Euros)  ($1 = 2.23 Brazilian reais)    (Compiled by Sneha Banerjee and Natalie Grover in Bangalore)",2014-04-07,MNK,"Mon Apr 7, 2014 | 4:03pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0MZ1RX20140407?type=companyNews
12,"  * To pay $86.10 per Questcor share, a premium of 27 pct* MS drug Acthar Gel sales expected to hit $1.9 bln in 2018* Mallinckrodt shares fall as much as 10 pct   (Adds analyst comment, updates shares)By Esha DeyApril 7 Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which is set to hit sales of $1 billion this year.The acquisition is Dublin-based Mallinckrodt's second in less than two months as it pushes into the lucrative specialty drugs market, which focuses on complex and chronic diseases.Mallinckrodt's shareholders took a dim view of the deal, however, pushing the company's shares down as much as 10 percent.Questcor has been facing federal probes into its marketing practices related to Acthar and multiple accusations from short-seller Citron Research.The company's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share held, for a total value of about $86.10 per Questcor share, the companies said in a statement on Monday.Questcor's shares were trading at $77 on the Nasdaq on Monday afternoon. Mallinckrodt was down 6 percent at $58.50 on the New York Stock Exchange.The deal - the latest in a series of acquisitions structured to take advantage of Ireland's low corporate tax rate - represents a 27 percent premium to Questcor's Friday close. Acthar is approved by the U.S. Food and Drug Administration for 19 conditions, many of which are associated with autoimmune and inflammatory diseases, including multiple sclerosis and infantile spasms.""We currently expect solid double-digit revenue growth for Acthar to continue in the future, driven by educational efforts and further expansion into indications currently on the Acthar label,"" Mallinckrodt Chief Executive Mark Trudeau said on a conference call.Almost all of Questcor's revenue comes from the drug, which had annual sales of about $760 million in 2013, an increase of about 50 percent from 2012. The company acquired the drug from Aventis for $100,000 in 2001.Questcor's stock fell to below $20 in September 2012 as U.S. government agencies, including the Securities and Exchange Commission, launched investigations into the company's marketing practices and health insurer Aetna Inc cut  reimbursement for the drug. The investigations are still on.The company has also faced repeated accusations from short-seller Citron Research regarding the drug's high price and Acthar's composition.The injectable drug, a formulation of pituitary hormones extracted from pigs, is priced at about $30,000 per vial. Acthar is expected to touch $1.9 billion in sales in 2018, according to Thomson Reuters data.Originally developed as a treatment for infantile spasms, Acthar has an orphan drug exclusivity until Oct. 15, 2017 for the indication.FAIR VALUE? The deal values Questcor at 12 times forward earnings, well below the median of 18.4 for the broader pharmaceutical industry, according to Thomson Reuters StarMine data. In the 12 months to Friday's close, Questcor's stock had risen more than 125 percent. Still, the stock trades at a strong discount to its median 10-year historical price-to-earnings ratio.Stocks of several high-growth biotechnology companies, which led a rally in the broader market in 2013, fell on Friday, making investors anxious about how much further they may fall.Barclays analyst Ying Huang said the recent selloff in biotech stocks puts more companies in the ""sweet spot,"" with a market capitalization of $1 billion to $10 billion, where potential acquirers might give them a look.Big pharmaceutical companies facing patent expirations still need to replenish pipelines, he said.Mallinckrodt, which traces its roots back to 1840 in St. Louis, Missouri, makes drugs for pain management, cerebral and spinal spasticity, inflammatory diseases and depression. It also makes generic drugs and active pharmaceutical ingredients.The company, which bought Cadence Pharmaceuticals Inc  for $1.3 billion in February, had revenue of $2.2 billion in 2013.Mallinckrodt, which was spun off from Covidien Plc  in July last year, said it expected the deal to add to adjusted earnings in 2014 and significantly boost adjusted profit in 2015.Mallinckrodt will fund the deal through cash on hand and debt financing from Barclays, which also advised the company. The deal is expected to be completed in the third quarter.Wachtell, Lipton, Rosen & Katz and Arthur Cox were Mallinckrodt's legal advisers in Ireland.Centerview Partners was Questcor's financial adviser, and Latham & Watkins LLP and Matheson were its legal advisers in Ireland.   (Additional reporting by Susan Kelly; Editing by Kirti Pandey and Saumyadeb Chakrabarty)",2014-04-07,MNK,"Mon Apr 7, 2014 | 2:46pm EDT",UPDATE 4-Mallinckrodt to buy Questcor for lucrative MS drug,http://www.reuters.com//article/questcor-offer-idUSL3N0MZ29F20140407?type=companyNews
13,"  * Internet stocks tumble; Yahoo shares down nearly 5 pct* Utilities, consumer staples in positive territory* Indexes down: Dow 0.9 pct; S&P 1.2 pct; Nasdaq 1.7 pct   (Updates to afternoon session)By Angela MoonNEW YORK, April 7 U.S. stocks fell sharply on Monday, putting the S&P 500 on track for its biggest three-day drop in two months, as investors bid down Internet stocks which had outperformed recently and rotated into defensive names to protect against further declines.Internet stocks were the day's biggest decliners with Amazon.com down 2.8 percent at $314.02, Yahoo! Inc  off 4.6 percent at $32.67 and Google Inc down 1.9 percent at $532.78. The Global X Social Media ETF  which includes Facebook and LinkedIn fell 3.4 percent to $17.91. Momentum shares - stocks in fast-growing industries which had seen their stock prices rocket in recent weeks - stabilized after their decline helped fuel a sell-off on Friday.But selling pressure migrated to other sectors, with only defensives such as utilities and consumer staples  in positive territory among the 10 major S&P sectors.""This type of market behavior (buyers favoring defensive names) suggests investors are turning cautious again after the big gains in stocks during the past year,"" said Gary Thayer, chief macro strategist at Wells Fargo Advisors. ""We remain long-term positive on the U.S. economy and the U.S. stock market but expect increased volatility risk this spring and summer.""Dish Network Corp was among the top decliners on the Nasdaq 100, down 6.2 percent at $58.37.The Dow Jones industrial average fell 149.25 points or 0.91 percent, to 16,263.46, the S&P 500 lost 21.82 points, or 1.17 percent, to 1,843.27 and the Nasdaq Composite  dropped 70.286 points, or 1.7 percent, to 4,057.439. Pfizer Inc, which was down 3.1 percent to $31.17, added pressure to the Dow and S&P 500. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.Earnings season gets under way this week, with results due from financials JPMorgan Chase & Co and Wells Fargo & Co , as well as retailer Bed, Bath & Beyond.S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent.A lackluster first-quarter earnings season hurt by a harsh winter could spark a pullback, some analysts said, with investors more optimistic for the second quarter.Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares climbed 13.5 percent to $77.05 while Mallinckrodt dropped 9.4 percent to $56.65.     (Additional reporting by Chuck Mikolajczek; Editing by Bernadette Baum)",2014-04-07,MNK,"Mon Apr 7, 2014 | 2:33pm EDT",US STOCKS-S&P 500 on track for worst 3-day decline since late-Jan,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ17D20140407?type=companyNews
14,"  * Pfizer weighs on Dow, S&P 500* Mallinckrodt to buy Questcor for $5.6 bln* MannKind stumbles; FDA extends drug review date* Indexes down: Dow 0.77 pct, S&P 0.76 pct, Nasdaq 0.97 pct   (Updates to midday)By Chuck MikolajczakNEW YORK, April 7 U.S. stocks fell on Monday, putting the S&P 500 on track for its biggest three-day drop in two months, as investors rotated into defensive names to protect against further declines.Momentum shares - stocks in fast-growing industries which had seen their stock prices rocket higher in recent weeks - managed to stabilize after their decline helped fuel a sell-off on Friday. But selling pressure migrated to other sectors, with only defensives such as utilities and consumer staples  in positive territory among the 10 major S&P sectors. ""We are definitely seeing a little more downside, a continuation from the nasty reversal on Friday,"" said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati, Ohio.""The big concern is the overall underlying weakness in so many different stocks. The picture isn't nearly as pretty when you look under the hood and you see various sectors have clearly broken down and now it's starting to pull down on the whole entire stock market.""Pfizer Inc, which was down 3 percent to $31.17, added pressure to the Dow and S&P 500. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The Dow Jones industrial average was down 126.35 points, or 0.77 percent, at 16,286.36. The Standard & Poor's 500 Index was down 14.26 points, or 0.76 percent, at 1,850.83. The Nasdaq Composite Index was down 39.89 points, or 0.97 percent, at 4,087.83.Earnings season gets under way this week, with results due from financials JPMorgan Chase & Co and Wells Fargo & Co , as well as retailer Bed, Bath & Beyond. S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent.A lackluster first-quarter earnings season hurt by a harsh winter could spark a pullback, some analysts said, with investors more optimistic for the second quarter.Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares climbed 13.5 percent to $77.05 while Mallinckrodt dropped 9.4 percent to $56.65.Energen Corp said it would sell its natural gas utility Alabama Gas Corp (Alagasco) to Laclede Group Inc  for $1.28 billion in cash to focus on oil and gas exploration and production. Energen shed 0.5 percent to $81.13 and Laclede lost 1.2 percent to $45.66.MannKind Corp slumped 10 percent to $6.18. The company said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months.     (Editing by Nick Zieminski and Bernadette Baum)",2014-04-07,MNK,"Mon Apr 7, 2014 | 12:27pm EDT","US STOCKS-Wall Street falls on broad weakness, Pfizer drags",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ0VQ20140407?type=companyNews
15,"  * Pfizer weighs on Dow, S&P 500* Mallinckrodt to buy Questcor for $5.6 bln* MannKind stumbles; FDA extends drug review date* Dow down 0.17 pct, S&P down 0.08 pct, Nasdaq up 0.09 pct   (Updates to open, adds quote)By Chuck MikolajczakNEW YORK, April 7 U.S. stocks were little changed on Monday, as recent weakness in so-called momentum names appeared to abate while a decline in shares of Pfizer  weighed on the market.Declines in momentum shares - fast-growing companies which have outperformed the market recently - have left investors anxious about how much further they may fall. That weakness continued early on Monday, with names such as TripAdvisor Inc down 1.6 percent to $84.30. However, other names such as Facebook Inc, up 1 percent to $57.33 and Gilead Sciences Inc, up 0.8 percent at $72.76, were able to reverse initial declines.""There is a difference between that sense you get when it is picking up speed and becoming a one-way juggernaut either way, to the downside or the upside, and we are not seeing that,"" said Gordon Charlop, a managing director at Rosenblatt Securities in New York.""We'll stick it out and see where they finally decide to step in but there is nobody here who is sensing there isn't going to be a point where that happens."" Earnings season gets under way this week, with results from financials JPMorgan Chase & Co and Wells Fargo & Co , as well as retailer Bed, Bath & Beyond.Pfizer Inc, down 2.5 percent to $31.37, also added pressure to the Dow and S&P 500. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent. A lackluster first-quarter earnings season impacted by harsh winter weather could spark a pullback, according to some analysts, with investors looking for optimism for the second quarter.The Dow Jones industrial average was down 27.36 points, or 0.17 percent, at 16,385.35. The Standard & Poor's 500 Index was down 1.53 points, or 0.08 percent, at 1,863.56. The Nasdaq Composite Index was up 3.72 points, or 0.09 percent, at 4,131.44.Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares surged 20.9 percent to $82.04 while Mallinckrodt shed 1.2 percent to $61.77.Energen Corp said it would sell its natural gas utility Alabama Gas Corp (Alagasco) to Laclede Group Inc  for $1.28 billion in cash to focus on oil and gas exploration and production. Energen gained 1.9 percent to $83.08 and Laclede lost 2.3 percent to $45.17.MannKind Corp slumped 8.9 percent to $6.26. The company said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months.     (Editing by Nick Zieminski and Bernadette Baum)",2014-04-07,MNK,"Mon Apr 7, 2014 | 10:40am EDT",US STOCKS-Wall St flat as momentum stocks stabilize; Pfizer drags,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ0MS20140407?type=companyNews
16,"  * Mallinckrodt to buy Questcor for $5.6 bln* MannKind stumbles; FDA extends review date for insulin treatment* Futures off: Dow 54 pts, S&P 7.5 pts, Nasdaq 29.25 pts   (Updates prices)By Chuck MikolajczakNEW YORK, April 7 U.S. stocks were set for a lower open on Monday, putting the S&P 500 on track for its third straight decline, as weakness in momentum names that sent the Nasdaq and benchmark S&P index to their worst drop since February in the prior session appeared poised to continue. * Declines in momentum names such as Netflix Inc  and TripAdvisor Inc overshadowed the relatively strong March payrolls report on Friday, leaving investors anxious about how much further they may fall. Facebook Inc lost 1.3 percent to $56 in premarket trade.* Earnings season gets under way this week, with earnings expected from financials JPMorgan Chase & Co and Wells Fargo & Co, as well as retailer Bed, Bath & Beyond .* S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent. * A lackluster first-quarter earnings season impacted by harsh winter weather could spark a pullback, according to some analysts, with investors looking for optimism for the second quarter.* S&P 500 e-mini futures fell 7.5 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures lost 54 points and Nasdaq 100 futures declined 29.25 points. * Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares surged 31.5 percent to $89.25 while Mallinckrodt rose 8.5 percent to $67.80 in premarket.* MannKind Corp slumped 10.2 percent to $6.17 before the opening bell. The company said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months.* Pfizer Inc shares fell 2.8 percent to $31.25 in premarket trade. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.    (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski)",2014-04-07,MNK,"Mon Apr 7, 2014 | 8:37am EDT",US STOCKS-Wall St to open lower as momentum stocks stay weak,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ0E220140407?type=companyNews
17,"  * Mallinckrodt to buy Questcor for $5.6 bln* MannKind stumbles; FDA extends review date for insulin treatment* Futures off: Dow 57 pts, S&P 8.25 pts, Nasdaq 29 ptsBy Chuck MikolajczakNEW YORK, April 7 U.S. stock index futures fell on Monday, putting the S&P 500 on track for its third straight decline, after weakness in momentum names sent the Nasdaq and benchmark S&P index to their worst drop since February in the prior session.* Declines in momentum names such as Netflix Inc  and TripAdvisor Inc overshadowed the relatively strong March payrolls report on Friday, leaving investors anxious about how much further they may fall. Facebook Inc lost 1.1 percent to $56.14 in premarket trade. * Earnings season gets under way this week, with earnings expected from financials JPMorgan Chase & Co and Wells Fargo & Co, as well as retailer Bed, Bath & Beyond  expected.* S&P 500 companies' first-quarter earnings are projected to have increased just 1.2 percent from a year ago, Thomson Reuters data showed. The forecast is down sharply from the start of the year, when growth was estimated at 6.5 percent. * A lackluster first-quarter earnings season impacted by harsh winter weather could spark a pullback, according to some analysts, with investors looking for optimism for the second quarter.S&P 500 e-mini futures fell 8.25 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures lost 57 points and Nasdaq 100 futures declined 29 points.* Specialty pharmaceuticals company Mallinckrodt Plc  agreed to buy drugmaker Questcor Pharmaceuticals Inc  for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel. Questcor shares surged 34.1 percent to $91 while Mallinckrodt rose 10.4 percent to $69 in premarket. * MannKind Corp slumped 11.9 percent to $6.05 before the opening bell. The company said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months.* Pfizer Inc shares fell 2.1 percent to $31.50 in premarket trade. The company's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.* European stocks dropped, halting a three-week rally and tracking the selloff on Wall Street on Friday.*  Japanese shares were hit on Monday by a one-two combination of a higher yen and a selloff in the tech sector.     (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski)",2014-04-07,MNK,"Mon Apr 7, 2014 | 7:47am EDT",US STOCKS-Futures fall in wake of Friday selloff,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0MZ0CC20140407?type=companyNews
18,"  Specialty drugmaker Mallinckrodt Plc (MNK.N) reported a smaller quarterly loss and raised its full-year profit and revenue forecast, citing strong sales of its recently acquired pain drug Ofirmev.Mallinckrodt reported a net loss of $24.1 million, or 41 cents per share, for the third quarter ended June 27, compared with $27.9 million, or 48 cents per share, a year earlier.On an adjusted basis, the company earned $1.20 per share.  Revenue jumped 14.6 percent to $653.1 million. The company said it expects full-year earnings of $4-$4.3 per share on revenue of $2.35 billion-$2.45 billion. It had earlier forecast 2014 earnings of $3.30-3.60 per share on revenue of $2.28 billion-$2.38 billion.  (Reporting by Anand Basu in Bangalore; Editing by Joyjeet Das)",2014-08-07,MNK,"Thu Aug 7, 2014 | 7:32am EDT",Mallinckrodt raises full-year forecast after smaller loss,http://www.reuters.com//article/us-malinckrodt-results-idUSKBN0G716Z20140807?type=companyNews
19,"  Aug 7 Specialty drugmaker Mallinckrodt Plc  reported a smaller quarterly loss and raised its full-year profit and revenue forecast, citing strong sales of its recently acquired pain drug Ofirmev.Mallinckrodt reported a net loss of $24.1 million, or 41 cents per share, for the third quarter ended June 27, compared with $27.9 million, or 48 cents per share, a year earlier. On an adjusted basis, the company earned $1.20 per share. Revenue jumped 14.6 percent to $653.1 million. The company said it expects full-year earnings of $4-$4.3 per share on revenue of $2.35 billion-$2.45 billion. It had earlier forecast 2014 earnings of $3.30-3.60 per share on revenue of $2.28 billion-$2.38 billion.   (Reporting by Anand Basu in Bangalore; Editing by Joyjeet Das)",2014-08-07,MNK,"Thu Aug 7, 2014 | 7:27am EDT",Mallinckrodt raises full-year forecast after smaller loss,http://www.reuters.com//article/malinckrodt-results-idUSL4N0QD3NW20140807?type=companyNews
20,  Aug 14   * S&P Dow jones indices says Mallinckrodt Plc to replace Rowan cosin S&P 500  * S&P Dow jones indices says Rowan to replace Mallinckrodt in S&P midcap 400  * S&P Dow jones indices says changes to be made after close of trading on  August 18 ,2014-08-14,MNK,"Thu Aug 14, 2014 | 5:22pm EDT",BRIEF-Mallinckrodt to replace Rowan in S&P 500,http://www.reuters.com//article/sp500-brief-idUSWEN00DW620140814?type=companyNews
21,"  THOMSON REUTERS, Aug 14,2014 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                           Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Daily earnings hits & misses         Meetings - Weekly                 Economic Indicators                              Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, now click on Related Co Data, now click on Co Events.                 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  13 Aug     13:00          Demandware at Canaccord Genuity Growth Conf 13 Aug     13:00           Ducommun at Canaccord Genuity Growth Conf 13 Aug     13:00        Inventure Foods at Canaccord Genuity Growth Conf 13 Aug     13:00        TeleCommunication at Jefferies Global Ind Conf 13 Aug     13:00           Timken Co at Jefferies Global Ind Conf 13 Aug     13:05        FireEye at Oppenheimer Internet & Communications Conf 13 Aug     13:05           Red Hat at Oppenheimer Internet & Communications Conf 13 Aug     13:05        Rocket Fuel at Oppenheimer Internet & Communications Conf 13 Aug     13:10        Cepheid at Wedbush Life Sciences Conf 13 Aug     13:10        MEI Pharma at Wedbush Life Sciences Conf 13 Aug     13:10        Relypsa at Wedbush Life Sciences Conf 13 Aug     13:20           Asbury Automotive at JPMorgan Auto Conf 13 Aug     13:30          AGCO at Jefferies Global Ind Conf 13 Aug     13:30           Esco Tech at Canaccord Genuity Growth Conf 13 Aug     13:30        Exactech at Canaccord Genuity Growth Conf 13 Aug     13:30        GenMark Diagnostics at Canaccord Genuity Growth Conf 13 Aug     13:30        Glowpoint at Canaccord Genuity Growth Conf 13 Aug     13:30        Mercury at Jefferies Global Ind Conf 13 Aug     13:30            Reliance Steel and Aluminum Co at Jefferies Global Ind Conf 13 Aug     13:45           CenturyLink at Oppenheimer Internet & Communications Conf 13 Aug     13:45        Durata Therapeutics at Wedbush Life Sciences Conf 13 Aug     13:45        Microsemi at Oppenheimer Internet & Communications Conf 13 Aug     13:45             Pandora Media at Oppenheimer Internet & Communications Conf 13 Aug     13:45        Regulus Therapeutics at Wedbush Life Sciences Conf 13 Aug     13:45        Rubicon Tech at Oppenheimer Internet & Communications Conf 13 Aug     00:00           Blount at Jefferies Global Ind Conf 13 Aug     00:00           Engility Holdings at Jefferies Global Ind Conf 13 Aug     12:00        Balchem at Canaccord Genuity Growth Conf 13 Aug     12:00        Constant Contact at Canaccord Genuity Growth Conf 13 Aug     12:00           CryoLife at Canaccord Genuity Growth Conf 13 Aug                  Garmin Ltd at Oppenheimer Internet & Communications Conf 13 Aug     12:00        NANOSPHERE at Canaccord Genuity Growth Conf 13 Aug                     Range Resources at Canaccord Genuity Growth Conf 13 Aug     12:00        Sizmek at Canaccord Genuity Growth Conf 13 Aug                  Summer Infant Annual Shareholders Meeting 13 Aug     12:00        Synageva Biopharma at Canaccord Genuity Growth Conf 13 Aug     12:00           Taminco at Jefferies Global Ind Conf 13 Aug     12:00           TRW Automotive Holdings at JPMorgan Auto Conf 13 Aug     12:30        Astec Industries at Jefferies Global Ind Conf 13 Aug     12:30        AtriCure at Canaccord Genuity Growth Conf 13 Aug     12:30       Chromadex at Canaccord Genuity Growth Conf 13 Aug     12:30            Curtiss-Wright at Jefferies Global Ind Conf 13 Aug     12:30           Darling Ingredients at Jefferies Global Ind Conf 13 Aug     12:30            Headwaters at Canaccord Genuity Growth Conf 13 Aug     12:30        Marketo at Canaccord Genuity Growth Conf 13 Aug     12:30           Oshkosh at Jefferies Global Ind Conf 13 Aug     12:30        Versartis at Canaccord Genuity Growth Conf 13 Aug     12:35        Anacor Pharmaceuticals at Wedbush Life Sciences Conf 13 Aug     12:35        OvaScience at Wedbush Life Sciences Conf 13 Aug     12:35        XOMA at Wedbush Life Sciences Conf 13 Aug     14:00           Alere at Canaccord Genuity Growth Conf 13 Aug     14:00           Computer Sciences Annual Shareholders Meeting 13 Aug     14:00           Cooper Tire & Rubber Co at JPMorgan Auto Conf 13 Aug     14:00         CPI Aerostructures at Jefferies Global Ind Conf 13 Aug     14:00           Ecolab at Canaccord Genuity Growth Conf 13 Aug     14:00          Generac Holdings at Canaccord Genuity Growth Conf 13 Aug     14:00          Globus Medical at Canaccord Genuity Growth Conf 13 Aug     14:00        Glu Mobile at Canaccord Genuity Growth Conf 13 Aug     14:00           Huntsman at Jefferies Global Ind Conf 13 Aug     14:00           MSA Safety at Jefferies Global Ind Conf 13 Aug     14:15        TASER at Oppenheimer Internet & Communications Conf 13 Aug     14:20        Intercept Pharmaceuticals at Wedbush Life Sciences Conf 13 Aug     14:20        Oncothyreon at Wedbush Life Sciences Conf 13 Aug     14:30           Belden at Canaccord Genuity Growth Conf 13 Aug     14:30           EnPro Industries at Jefferies Global Ind Conf 13 Aug     14:30           Exelis at Jefferies Global Ind Conf 13 Aug     14:30        Genomic Health at Canaccord Genuity Growth Conf 13 Aug     14:30          Global Power Equipment at Jefferies Global Ind Conf 13 Aug     14:30        Innophos Holdings at Jefferies Global Ind Conf 13 Aug     14:30        Radius Health at Canaccord Genuity Growth Conf 13 Aug     14:30        Rent-A-Center at Canaccord Genuity Growth Conf 13 Aug     14:30        Viaat Canaccord Genuity Growth Conf 13 Aug     14:30        ZELTIQ Aesthetics at Canaccord Genuity Growth Conf 13 Aug     14:55        BIND Therapeutics at Wedbush Life Sciences Conf 13 Aug     15:00        Cogent Communications at Canaccord Genuity Growth Conf 13 Aug     15:00        ePlus at Canaccord Genuity Growth Conf 13 Aug     15:00           J M Smucker Co Annual Shareholders Meeting 13 Aug     15:00        Maxwell Tech at Canaccord Genuity Growth Conf 13 Aug     15:00        NuVasive at Canaccord Genuity Growth Conf 13 Aug     15:00        OraSure Tech at Canaccord Genuity Growth Conf 13 Aug     15:00        The Chefs' Warehouse at Canaccord Genuity Growth Conf 13 Aug     15:05           ADT at Oppenheimer Internet & Communications Conf 13 Aug     15:05        Akamai Tech at Oppenheimer Internet & Communications Conf 13 Aug     15:05        Sonus Networks at Oppenheimer Internet & Communications Conf 13 Aug     15:05          Yelp at Oppenheimer Internet & Communications Conf 13 Aug     15:20           Lear at JPMorgan Auto Conf 13 Aug     15:30        Aerie Pharmaceuticals at Canaccord Genuity Growth Conf 13 Aug     15:30        Alphatec Holdings at Canaccord Genuity Growth Conf 13 Aug     15:30        Boulder Brands at Canaccord Genuity Growth Conf 13 Aug     15:30        Equinix at Canaccord Genuity Growth Conf 13 Aug     15:30        Exact Sciences at Canaccord Genuity Growth Conf 13 Aug     15:30        GT Advanced Tech at Canaccord Genuity Growth Conf 13 Aug     15:30        PC Connection at Canaccord Genuity Growth Conf 13 Aug     15:55             AT&T at Oppenheimer Internet & Communications Conf 13 Aug                     Nuverra Environmental Solutions at Jefferies Global Ind Conf 13 Aug     16:00        Rentrak Annual Shareholders Meeting 13 Aug     16:20          Delphi Automotive PLC at JPMorgan Auto Conf 13 Aug     16:30           Albemarle at Jefferies Global Ind Conf 13 Aug     16:35          T-Mobile Us at Oppenheimer Internet & Communications Conf 13 Aug     16:45        Biodel at Wedbush Life Sciences Conf 13 Aug     16:45         Foundation Medicine at Wedbush Life Sciences Conf 13 Aug     17:00           3D at Canaccord Genuity Growth Conf 13 Aug     17:00          Chemtura at Jefferies Global Ind Conf 13 Aug     17:00             Pandora Media at Canaccord Genuity Growth Conf 13 Aug     17:00           Penske Automotive at JPMorgan Auto Conf 13 Aug     17:00           Snap-On at Jefferies Global Ind Conf 13 Aug     17:00        STAAR Surgical Co at Canaccord Genuity Growth Conf 13 Aug     17:00        Ultimate Software at Canaccord Genuity Growth Conf 13 Aug     17:15        Informatica at Oppenheimer Internet & Communications Conf 13 Aug     17:20        Oxygen Biotherapeutics at Wedbush Life Sciences Conf 13 Aug     17:30          GrubHub at Canaccord Genuity Growth Conf 13 Aug     17:30           Lannett Company at Canaccord Genuity Growth Conf 13 Aug     17:30        Sequential Brands at Canaccord Genuity Growth Conf 13 Aug     17:30        Veeco Instruments at Canaccord Genuity Growth Conf 13 Aug     17:30        Volcano at Canaccord Genuity Growth Conf 13 Aug     17:40           Harman Industries at JPMorgan Auto Conf 13 Aug     17:55        MacroGenics at Wedbush Life Sciences Conf 13 Aug     17:55        Monolithic Power at Oppenheimer Internet & Communications Conf 13 Aug     18:00         Exa at Canaccord Genuity Growth Conf 13 Aug     18:00        NewLink Genetics at Canaccord Genuity Growth Conf 13 Aug     18:00           Regal Beloit at Jefferies Global Ind Conf 13 Aug     18:00        Steven Madden Ltd at Canaccord Genuity Growth Conf 13 Aug     18:00        Thoratec at Canaccord Genuity Growth Conf 13 Aug     18:00        Xilinx Annual Shareholders Meeting 13 Aug     18:00           Zillow at Canaccord Genuity Growth Conf 13 Aug     18:25        Cavium at Oppenheimer Internet & Communications Conf 13 Aug     18:30        AcelRx Pharmaceuticals at Canaccord Genuity Growth Conf 13 Aug     18:30        Atmel at Canaccord Genuity Growth Conf 13 Aug     18:30        GTX at Wedbush Life Sciences Conf 13 Aug     18:30        OHR Pharmaceutical at Wedbush Life Sciences Conf 13 Aug     18:30          Science Applications at Jefferies Global Ind Conf 13 Aug     18:30        Spectranetics at Canaccord Genuity Growth Conf 13 Aug     18:30        Tetraphase Pharmaceuticals at Wedbush Life Sciences Conf 13 Aug     18:30         TriMas Corp. at Jefferies Global Ind Conf 13 Aug     18:30        Ultratech at Canaccord Genuity Growth Conf 13 Aug     18:35          Ellie Mae at Oppenheimer Internet & Communications Conf 13 Aug     18:35          Imperva at Oppenheimer Internet & Communications Conf 13 Aug     18:35        Internap Network at Oppenheimer Internet & Communications Conf 13 Aug     18:35        Qualcomm at Oppenheimer Internet & Communications Conf 13 Aug     19:00           A. O. Smith at Jefferies Global Ind Conf 13 Aug     19:00        Apricus Biosciences at Canaccord Genuity Growth Conf 13 Aug     19:00        Avanir Pharmaceuticals at Canaccord Genuity Growth Conf 13 Aug     19:00        E2open at Canaccord Genuity Growth Conf 13 Aug     19:00        InterMune at Canaccord Genuity Growth Conf 13 Aug     19:05        Cerulean Pharma at Wedbush Life Sciences Conf 13 Aug     19:05          Everyday Health at Oppenheimer Internet & Communications Conf 13 Aug     19:05          Inphi at Oppenheimer Internet & Communications Conf 13 Aug     19:15        CalAmp at Oppenheimer Internet & Communications Conf 13 Aug     19:15        Comverse at Oppenheimer Internet & Communications Conf 13 Aug     19:15        Integrated Device at Oppenheimer Internet & Communications Conf 13 Aug     19:30        Cynosure at Canaccord Genuity Growth Conf 13 Aug     19:30        Immunogen at Canaccord Genuity Growth Conf 13 Aug     19:30        Insmed at Canaccord Genuity Growth Conf 13 Aug     19:30        MKS Instruments at Canaccord Genuity Growth Conf 13 Aug     19:30       MusclePharm at Canaccord Genuity Growth Conf 13 Aug     19:30        Renewable Energy at Canaccord Genuity Growth Conf 13 Aug     19:30           United Rentals at Jefferies Global Ind Conf 13 Aug     19:30           Zendesk at Canaccord Genuity Growth Conf 13 Aug     19:40        Hyperion Therapeutics at Wedbush Life Sciences Conf 13 Aug     19:40        Novavax at Wedbush Life Sciences Conf 13 Aug     19:40        Ultragenyx Pharmaceutical at Wedbush Life Sciences Conf 13 Aug     19:45        Energous at Oppenheimer Internet & Communications Conf 13 Aug     19:55        Intersil at Oppenheimer Internet & Communications Conf 13 Aug     19:55         Silicon Graphics at Oppenheimer Internet & Communications Conf 13 Aug     20:00        Benefitfocus at Canaccord Genuity Growth Conf 13 Aug     20:00        Cascade Microtech at Canaccord Genuity Growth Conf 13 Aug     20:00        Egalet at Canaccord Genuity Growth Conf 13 Aug     20:00        IROBOT at Canaccord Genuity Growth Conf 13 Aug     20:00          LifeLock at Canaccord Genuity Growth Conf 13 Aug     20:00         Nortek at Jefferies Global Ind Conf 13 Aug     20:00        Numerex at Canaccord Genuity Growth Conf 13 Aug     20:00        SCYNEXIS at Canaccord Genuity Growth Conf 13 Aug     20:30        Advanced Energy Industries at Canaccord Genuity Growth Conf 13 Aug     20:30        NxStage Medical at Canaccord Genuity Growth Conf 13 Aug     20:30        ORBCOMM at Canaccord Genuity Growth Conf 13 Aug     20:30          Paycom Software at Canaccord Genuity Growth Conf 13 Aug     20:30        Sarepta Therapeutics at Canaccord Genuity Growth Conf 13 Aug     20:30          Silver Spring Networks at Canaccord Genuity Growth Conf 13 Aug     21:00         Kofax Ltd at Canaccord Genuity Growth Conf 13 Aug     21:00        Lpath at Canaccord Genuity Growth Conf 13 Aug     21:00        Peregrine Semiconductor at Canaccord Genuity Growth Conf 13 Aug     21:00        Raptor Pharmaceutical at Canaccord Genuity Growth Conf 13 Aug     21:00         Uroplasty at Canaccord Genuity Growth Conf 14 Aug     13:00        HeartWare at Canaccord Genuity Growth Conf 14 Aug     13:00        Itron at Canaccord Genuity Growth Conf 14 Aug     13:00           MasTec at Jefferies Global Ind Conf 14 Aug     13:00        Revolution Lighting Tech at Canaccord Genuity Growth Conf 14 Aug     13:00           Spirit AeroHoldings at Jefferies Global Ind Conf 14 Aug     13:00        Stein Mart at Canaccord Genuity Growth Conf 14 Aug     13:00        World Energy Solutions at Canaccord Genuity Growth Conf 14 Aug     13:30        Altra Industrial Motion at Jefferies Global Ind Conf 14 Aug     13:30           Badger Meter at Canaccord Genuity Growth Conf 14 Aug     13:30         CPI Aerostructures at Canaccord Genuity Growth Conf 14 Aug     13:30        Lifetime Brands at Canaccord Genuity Growth Conf 14 Aug     13:30        MEI Pharma at Canaccord Genuity Growth Conf 14 Aug     13:30        Merit Medical at Canaccord Genuity Growth Conf 14 Aug     13:30           Teledyne Tech at Jefferies Global Ind Conf 14 Aug     00:00           Hexcel at Jefferies Global Ind Conf 14 Aug     12:00        AngioDynamics at Canaccord Genuity Growth Conf 14 Aug     12:00          Care.com at Canaccord Genuity Growth Conf 14 Aug     12:00           Honeywell at Jefferies Global Ind Conf 14 Aug     12:00           Packaging of America at Jefferies Global Ind Conf 14 Aug     12:00        Questcor Pharmaceuticals Extraordinary Shareholders Meeting 14 Aug     12:00        Rubicon Tech at Canaccord Genuity Growth Conf 14 Aug     12:00         SciQuest at Canaccord Genuity Growth Conf 14 Aug     12:30        ARC Worldwide at Canaccord Genuity Growth Conf 14 Aug     12:30           Darling Ingredients at Canaccord Genuity Growth Conf 14 Aug     12:30        Destination XL at Canaccord Genuity Growth Conf 14 Aug     12:30        Endologix at Canaccord Genuity Growth Conf 14 Aug     12:30        HomeAway at Canaccord Genuity Growth Conf 14 Aug     12:30        SPS Commerce at Canaccord Genuity Growth Conf 14 Aug     12:30            Willbros at Jefferies Global Ind Conf 14 Aug     14:00           Alliance One Annual Shareholders Meeting 14 Aug     14:00            Boeing Co at Jefferies Global Ind Conf 14 Aug     14:00        CECO Environmental at Canaccord Genuity Growth Conf 14 Aug     14:00           Heico at Canaccord Genuity Growth Conf 14 Aug     14:00        NPS Pharmaceuticals at Canaccord Genuity Growth Conf 14 Aug     14:00        RTI Surgical at Canaccord Genuity Growth Conf 14 Aug     14:00           Tutor Perini at Jefferies Global Ind Conf 14 Aug     14:30        Anika Therapeutics at Canaccord Genuity Growth Conf 14 Aug     14:30        Bottomline Tech at Canaccord Genuity Growth Conf 14 Aug     14:30        Cytokinetics at Canaccord Genuity Growth Conf 14 Aug     14:30           Ducommun at Jefferies Global Ind Conf 14 Aug     14:30        Five9 at Canaccord Genuity Growth Conf 14 Aug     14:30        Lumos Networks at Canaccord Genuity Growth Conf 14 Aug     14:30        TTM Tech at Canaccord Genuity Growth Conf 14 Aug     14:30        Ultragenyx Pharmaceutical at Canaccord Genuity Growth Conf 14 Aug     15:00        Cerulean Pharma at Canaccord Genuity Growth Conf 14 Aug     15:00           Fluor at Jefferies Global Ind Conf 14 Aug     15:00        GI Dynamics at Canaccord Genuity Growth Conf 14 Aug     15:00           Kennametal at Jefferies Global Ind Conf 14 Aug     15:00        Silicon Laboratories at Canaccord Genuity Growth Conf 14 Aug     15:00          The Rubicon Project at Canaccord Genuity Growth Conf 14 Aug     15:00        Zafgen at Canaccord Genuity Growth Conf 14 Aug     15:30        Akamai Tech at Canaccord Genuity Growth Conf 14 Aug     15:30        Datalink at Canaccord Genuity Growth Conf 14 Aug     15:30        EnteroMedics at Canaccord Genuity Growth Conf 14 Aug     15:30          InvenSense at Canaccord Genuity Growth Conf 14 Aug     15:30        XOMA at Canaccord Genuity Growth Conf 14 Aug     15:30          YuMe at Canaccord Genuity Growth Conf 14 Aug     16:00           Lennox at Jefferies Global Ind Conf 14 Aug     16:00        Qualcomm at Canaccord Genuity Growth Conf 14 Aug                     Quanta at Jefferies Global Ind Conf 14 Aug     16:30           Booz Allen Hamilton Holding at Jefferies Global Ind Conf 14 Aug     17:00           Belden at Jefferies Global Ind Conf 14 Aug     17:00        CalAmp at Canaccord Genuity Growth Conf 14 Aug     17:00          Castlight Health at Canaccord Genuity Growth Conf 14 Aug     17:00        Insulet at Canaccord Genuity Growth Conf 14 Aug     17:00           Mallinckrodt Plc Extraordinary Shareholders Meeting 14 Aug     17:00           Sonoco Products Co at Jefferies Global Ind Conf 14 Aug     17:00        Venaxis at Canaccord Genuity Growth Conf 14 Aug     17:30           Acuity Brands at Canaccord Genuity Growth Conf 14 Aug     17:30        Cancer Genetics at Canaccord Genuity Growth Conf 14 Aug     17:30        DexCom at Canaccord Genuity Growth Conf 14 Aug     17:30        GlycoMimetics at Canaccord Genuity Growth Conf 14 Aug     17:30       Hipcricket at Canaccord Genuity Growth Conf 14 Aug     17:30        MeetMe at Canaccord Genuity Growth Conf 14 Aug     17:30        NeuLion at Canaccord Genuity Growth Conf 14 Aug     17:30        PMFG at Jefferies Global Ind Conf 14 Aug     17:30        Trevena at Canaccord Genuity Growth Conf 14 Aug     18:00        Aegion at Jefferies Global Ind Conf 14 Aug     18:00           Medifast at Canaccord Genuity Growth Conf 14 Aug     18:00        MiMedx at Canaccord Genuity Growth Conf 14 Aug     18:00        Monotype Imaging Holdings at Canaccord Genuity Growth Conf 14 Aug     18:00        OSI at Jefferies Global Ind Conf 14 Aug     18:00        TriQuint Semiconductor at Canaccord Genuity Growth Conf 14 Aug     18:00        Vascular Solutions at Canaccord Genuity Growth Conf 14 Aug     18:30        Cree at Canaccord Genuity Growth Conf 14 Aug     18:30        Derma Sciences at Canaccord Genuity Growth Conf 14 Aug     18:30        Exponent at Jefferies Global Ind Conf 14 Aug     18:30        Mast Therapeutics at Canaccord Genuity Growth Conf 14 Aug     18:30        Reis at Canaccord Genuity Growth Conf 14 Aug     19:00        EnerNOC at Canaccord Genuity Growth Conf 14 Aug     19:00        Nuance Communications at Canaccord Genuity Growth Conf 14 Aug     19:00         Sunshine Heart at Canaccord Genuity Growth Conf 14 Aug     19:30        Anacor Pharmaceuticals at Canaccord Genuity Growth Conf 14 Aug     19:30        Autobytel at Canaccord Genuity Growth Conf 14 Aug     19:30        Digi at Canaccord Genuity Growth Conf 14 Aug     19:30        LeMaitre Vascular at Canaccord Genuity Growth Conf 14 Aug     19:30           NU Skin Enterprises at Canaccord Genuity Growth Conf 14 Aug     19:30          Proto Labs at Canaccord Genuity Growth Conf 14 Aug     19:30        Tearlab at Canaccord Genuity Growth Conf 14 Aug     19:30        Towerstream at Canaccord Genuity Growth Conf 14 Aug     20:00        Echelon at Canaccord Genuity Growth Conf 14 Aug     20:00        Momenta Pharmaceuticals at Canaccord Genuity Growth Conf 14 Aug     20:00        United Natural Foods at Canaccord Genuity Growth Conf 15 Aug     17:00           Superior Industries Annual Shareholders Meeting 15 Aug     07:00           Rowan Companies PLC Extraordinary Shareholders Meeting 15 Aug     20:00       Hancock Fabrics Annual Shareholders Meeting 18 Aug     22:00        Diamondback Energy at EnerCom The Oil & Gas Conf 18 Aug     22:25          Clayton Williams Energy at EnerCom The Oil & Gas Conf 18 Aug     22:25        Mid-Con Energy LP at EnerCom The Oil & Gas Conf 18 Aug     22:50           BPZ Resources at EnerCom The Oil & Gas Conf 18 Aug     22:50            SM Energy Co at EnerCom The Oil & Gas Conf 18 Aug     14:00           Range Resources at EnerCom The Oil & Gas Conf 18 Aug     14:25           Core Laboratories NV at EnerCom The Oil & Gas Conf 18 Aug     14:50           Cabot Oil & Gas at EnerCom The Oil & Gas Conf 18 Aug     15:15        Dawson Geophysical Co at EnerCom The Oil & Gas Conf 18 Aug     15:40           Whiting Petroleum at EnerCom The Oil & Gas Conf 18 Aug     16:30            Sanchez Energy at EnerCom The Oil & Gas Conf 18 Aug     16:55           Magnum Hunter Resources at EnerCom The Oil & Gas Conf 18 Aug     17:20        Synergy Resources at EnerCom The Oil & Gas Conf 18 Aug     17:45           VAALCO Energy at EnerCom The Oil & Gas Conf 18 Aug     19:30        Triangle Petroleum at EnerCom The Oil & Gas Conf 18 Aug     19:55         Greenhunter Resources at EnerCom The Oil & Gas Conf 18 Aug     19:55           Stone Energy at EnerCom The Oil & Gas Conf 18 Aug     20:20           Goodrich Petroleum at EnerCom The Oil & Gas Conf 18 Aug     20:20           Harvest Natural Resources at EnerCom The Oil & Gas Conf 18 Aug     20:45           Resolute Energy at EnerCom The Oil & Gas Conf 18 Aug     21:10         CAMAC Energy at EnerCom The Oil & Gas Conf 18 Aug     21:10           Laredo Petroleum at EnerCom The Oil & Gas Conf 18 Aug     21:35        Magellan Petroleum at EnerCom The Oil & Gas Conf 18 Aug     21:35           Oasis Petroleum at EnerCom The Oil & Gas Conf 19 Aug     22:00         Gastar Exploration at EnerCom The Oil & Gas Conf 19 Aug     22:00            Willbros at EnerCom The Oil & Gas Conf 19 Aug                     Buckeye LP at Citi MLP / Midstream Infrastructure Conf 19 Aug     14:00           Basic Energy at EnerCom The Oil & Gas Conf 19 Aug     14:00        UniPixel Annual Shareholders Meeting 19 Aug     14:25         Emerald Oil at EnerCom The Oil & Gas Conf 19 Aug     14:50           CARBO Ceramics at EnerCom The Oil & Gas Conf 19 Aug     14:50           QEP Resources at EnerCom The Oil & Gas Conf 19 Aug     15:15           Concho Resources at EnerCom The Oil & Gas Conf 19 Aug     15:15           Denbury Resources at EnerCom The Oil & Gas Conf 19 Aug     15:40         Evolution Petroleum at EnerCom The Oil & Gas Conf 19 Aug     16:05          Bonanza Creek Energy at EnerCom The Oil & Gas Conf 19 Aug     16:05        Linn Energy LLC at EnerCom The Oil & Gas Conf 19 Aug     16:30            PetroQuest Energy at EnerCom The Oil & Gas Conf 19 Aug     16:30        Saratoga Resources at EnerCom The Oil & Gas Conf 19 Aug     16:55        American Eagle Energy at EnerCom The Oil & Gas Conf 19 Aug     16:55        Approach Resources at EnerCom The Oil & Gas Conf 19 Aug     17:20           Cimarex Energy Co at EnerCom The Oil & Gas Conf 19 Aug     17:20           Flotek Industries at EnerCom The Oil & Gas Conf 19 Aug     17:45        Acorn Energy at EnerCom The Oil & Gas Conf 19 Aug     18:20           WPX Energy at EnerCom The Oil & Gas Conf 19 Aug     18:30         Uroplasty Annual Shareholders Meeting 19 Aug                  AcelRx Pharmaceuticals at Guggenheim LLC One on One Day 19 Aug     19:30           EQT at EnerCom The Oil & Gas Conf 19 Aug     19:55            Halcon Resources at EnerCom The Oil & Gas Conf 19 Aug     19:55           RPC at EnerCom The Oil & Gas Conf 19 Aug     20:20       Black Ridge Oil & Gas at EnerCom The Oil & Gas Conf 19 Aug     20:20           Callon Petroleum Co at EnerCom The Oil & Gas Conf 19 Aug     20:45          Atlas Energy LP at EnerCom The Oil & Gas Conf 19 Aug     21:10        Earthstone Energy at EnerCom The Oil & Gas Conf 19 Aug     21:10         Memorial Resource Development at EnerCom The Oil & Gas Conf 19 Aug     21:35        Carrizo Oil & Gas at EnerCom The Oil & Gas Conf 19 Aug     21:35           Energen at EnerCom The Oil & Gas Conf 20 Aug     00:00         Cheniere Energy LP at Citi MLP / Midstream Infrastructure Conf 20 Aug                     Atlas Pipeline LP at Citi MLP / Midstream Infrastructure Conf 20 Aug                  Rentrak at BWS Fin Growth and Value Summer Investor Series 20 Aug                    SunCoke Energy LP at Citi MLP / Midstream Infrastructure Conf 20 Aug     14:00        Escalera Resources Co at EnerCom The Oil & Gas Conf 20 Aug     14:00            Frank's NV at EnerCom The Oil & Gas Conf 20 Aug     14:25           Southwestern Energy at EnerCom The Oil & Gas Conf 20 Aug     14:30        Multi-Color Annual Shareholders Meeting 20 Aug     14:50          Miller Energy Resources at EnerCom The Oil & Gas Conf 20 Aug     14:50        PDC Energy at EnerCom The Oil & Gas Conf 20 Aug     15:00           La-Z-Boy Annual Shareholders Meeting 20 Aug     15:15           Midstates Petroleum Company at EnerCom The Oil & Gas Conf 20 Aug     15:40       Trans Energy at EnerCom The Oil & Gas Conf 20 Aug     15:40           Unit at EnerCom The Oil & Gas Conf 20 Aug     16:05           Endeavour at EnerCom The Oil & Gas Conf 20 Aug     16:05         Northern Oil and Gas at EnerCom The Oil & Gas Conf 20 Aug     16:30        Rosetta Resources at EnerCom The Oil & Gas Conf 20 Aug     17:20           Bill Barrett at EnerCom The Oil & Gas Conf 20 Aug     17:20           National Fuel Gas Co at EnerCom The Oil & Gas Conf 20 Aug     17:45        US Energy at EnerCom The Oil & Gas Conf 20 Aug     19:30        Torchlight Energy Resources at EnerCom The Oil & Gas Conf 20 Aug     20:20           Continental Resources at EnerCom The Oil & Gas Conf 20 Aug     20:20         TransAtlantic Petroleum Ltd at EnerCom The Oil & Gas Conf 20 Aug     21:35        EnerJex Resources at EnerCom The Oil & Gas Conf 20 Aug     21:35          New Source Energy LP at EnerCom The Oil & Gas Conf       FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2014-08-14,MNK,"Thu Aug 14, 2014 | 9:00am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL4N0QK55V20140814?type=companyNews
22,"   By Vidya L Nathan and Greg Roumeliotis  Dublin-based drugmaker Mallinckrodt Plc strengthened its presence in U.S. hospitals as it agreed to buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion.Shares of Mallinckrodt, a seller of generics, specialty drugs and medical imaging agents, jumped as much as 6.7 percent to a record $123.95.The deal gives Mallinckrodt access to INOmax, which Ikeria says is the only approved product to treat hypoxic respiratory failure in infants. The device that delivers nitric oxide has been available in the market for about a decade and a half.Hypoxic respiratory failure affects about 25,000-30,000 babies born each year in the United States. INOmax currently caters to about half of that population, Mallinckrodt CEO Mark Trudeau said in a call on Thursday.Ikaria, owned by a group of investors led by private equity firm Madison Dearborn Partners LLC, is testing INOmax for treating other breathing difficulties and a type of high blood pressure that affects arteries in the lungs and heart. Madison Dearborn will get 2.8 times the $224 million it invested in Hampton, New Jersey-based Ikaria a little over a year ago, a person familiar with the matter said. New Mountain Capital, which invested about $220 million in 2007, will receive as much as $880 million, other people familiar with the matter said.Analysts from at least three brokerages  BMO Capital, Leerink Swann and Oppenheimer & Co  said the deal made sense for Mallinckrodt. The deal comes a year after Mallinckrodt, spun off from Covidien Plc in 2013, bought Questcor Pharmaceuticals Inc for $5.2 billion.Mallinckrodt, which claims to have its products in almost every U.S. hospital, diagnostic imaging center and pharmacy, said it expects Ikeria to add at least $150 million to its sales and 25 cents to earnings per share for the year ending September. Mallinckrodt, which recorded sales of $866.3 million in its first quarter ended Dec. 26, plans to fund the deal with a combination of cash on hand and debt.Goldman Sachs is Mallinckrodt's financial adviser, and Wachtell Lipton Rosen & Katz and Arthur Cox in Ireland its legal advisers. Ikaria's legal adviser is Kirkland & Ellis LLP.Mallinckrodt shares were up 4.3 percent at $121.18 on the New York Stock Exchange in afternoon trading. (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Joyjeet Das)",2015-03-05,MNK,"Thu Mar 5, 2015 | 12:56pm EST",Mallinckrodt buys respiratory drug maker to boost hospital presence,http://www.reuters.com//article/us-malinckrodt-deal-idUSKBN0M11BS20150305?type=companyNews
23,"  * Ikeria owns only approved hypoxic respiratory failure treatment* Analysts view deal as strategic fit for Mallinckrodt* Shares rise as much as 6.7 pct to $123.95   (Adds comments from CEO, analysts, details; Updates shares)By Vidya L Nathan and Greg RoumeliotisMarch 5 Dublin-based drugmaker Mallinckrodt Plc  strengthened its presence in U.S. hospitals as it agreed to buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion.Shares of Mallinckrodt, a seller of generics, specialty drugs and medical imaging agents, jumped as much as 6.7 percent to a record $123.95. The deal gives Mallinckrodt access to INOmax, which Ikeria says is the only approved product to treat hypoxic respiratory failure in infants. The device that delivers nitric oxide has been available in the market for about a decade and a half.Hypoxic respiratory failure affects about 25,000-30,000 babies born each year in the United States. INOmax currently caters to about half of that population, Mallinckrodt CEO Mark Trudeau said in a call on Thursday.Ikaria, owned by a group of investors led by private equity firm Madison Dearborn Partners LLC, is testing INOmax for treating other breathing difficulties and a type of high blood pressure that affects arteries in the lungs and heart. Madison Dearborn will get 2.8 times the $224 million it invested in Hampton, New Jersey-based Ikaria a little over a year ago, a person familiar with the matter said.New Mountain Capital, which invested about $220 million in 2007, will receive as much as $880 million, other people familiar with the matter said.Analysts from at least three brokerages - BMO Capital, Leerink Swann and Oppenheimer & Co - said the deal made sense for Mallinckrodt. The deal comes a year after Mallinckrodt, spun off from Covidien Plc in 2013, bought Questcor Pharmaceuticals Inc for $5.2 billion.Mallinckrodt, which claims to have its products in almost every U.S. hospital, diagnostic imaging center and pharmacy, said it expects Ikeria to add at least $150 million to its sales and 25 cents to earnings per share for the year ending September.Mallinckrodt, which recorded sales of $866.3 million in its first quarter ended Dec. 26, plans to fund the deal with a combination of cash on hand and debt.Goldman Sachs is Mallinckrodt's financial adviser, and Wachtell Lipton Rosen & Katz and Arthur Cox in Ireland its legal advisers. Ikaria's legal adviser is Kirkland & Ellis LLP.Mallinckrodt shares were up 4.3 percent at $121.18 on the New York Stock Exchange in afternoon trading.   (Additional reporting by Rosmi Shaji in Bengaluru; Editing by Joyjeet Das)",2015-03-05,MNK,"Thu Mar 5, 2015 | 12:54pm EST",UPDATE 2-Mallinckrodt buys respiratory drug maker to boost hospital presence,http://www.reuters.com//article/malinckrodt-deal-idUSL4N0W74BR20150305?type=companyNews
24,"  March 5 Mallinckrodt Plc said it would buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion to expand its current offering of specialty products and critical care treatments.The deal is expected to add at least $150 million to Mallinckrodt's sales and 25 cents per share to its profit for the year ending September, the company said on Thursday.  Hampton, New Jersey-based Ikaria is owned by a group of investors led by private equity firm Madison Dearborn Partners LLC. Ikaria's INOmax device delivers nitric oxide to children suffering from a type of respiratory failure.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Joyjeet Das) ",2015-03-05,MNK,"Thu Mar 5, 2015 | 7:25am EST",Mallinckrodt to buy private respiratory drug & device maker for $2.3 bln,http://www.reuters.com//article/malinckrodt-deal-idUSL4N0W74A620150305?type=companyNews
25,"  Thomson Reuters March 16, 2015 - Corporate Meetings for US companies for Week ahead.         S&P 500 Earnings - MONTH AHEAD     Dividends                            Non S&P 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, now click on Related Co Data, now click on Co Events.                      - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DATE       GMT      SYMBOL       EVENT TITLE  16 Mar     13:10        Infinity Property and Casualty at NYSSA & Raymond James Conf 16 Mar     13:20          Alexander & Baldwin at Sidoti & CompanyForum 16 Mar     13:20        Merit Medical Systems at Sidoti & CompanyForum 16 Mar     13:20        Pool at Sidoti & CompanyForum 16 Mar     13:50          Crawford & Co at NYSSA & Raymond James Conf 16 Mar                     Dorian LPG Ltd at GHS Conf 16 Mar                  FuelCell Energy at Sidoti & CompanyForum 16 Mar                     International Shipholding at GHS Conf 16 Mar                     Invacare at Sidoti & CompanyForum 16 Mar                     MRC Global at GHS Conf 16 Mar                  Power Solutions International at GHS Conf 16 Mar                     Rogers at Sidoti & CompanyForum 16 Mar     12:30           Fidelity & Guaranty Life at NYSSA & Raymond James Conf 16 Mar     14:00            Vonage at Sidoti & CompanyForum 16 Mar     14:15           Coca-Cola Enterprises at CAGE Conf 16 Mar     14:40           Checkpoint Systems at Sidoti & CompanyForum 16 Mar     14:40        Hallmark Financial Services at NYSSA & Raymond James Conf 16 Mar     15:00           Cooper Companies Annual Shareholders Meeting 16 Mar     15:20        Argo Group International Ltd at NYSSA & Raymond James Conf 16 Mar     15:30        Viacom Annual Shareholders Meeting 16 Mar     16:00           FBL Financial Group at NYSSA & Raymond James Conf 16 Mar     17:00        United at NYSSA & Raymond James Conf 16 Mar     17:20        ePlus at Sidoti & CompanyForum 16 Mar     17:40        United Fire Group at NYSSA & Raymond James Conf 16 Mar     18:00           Cantel Medical at Sidoti & CompanyForum 16 Mar     18:30           ProAssurance at NYSSA & Raymond James Conf 16 Mar     18:40          GAIN Capital at Sidoti & CompanyForum 16 Mar     19:10           RLI at NYSSA & Raymond James Conf 17 Mar     13:00        Biodel Annual Shareholders Meeting 17 Mar     13:00           Cliffs Natural Resources at Platts North America Conf 17 Mar     13:05           Timken Co at Bank of America Conf 17 Mar     13:10        Federated National Holding Co at NYSSA & Raymond James Conf 17 Mar     13:15           International Flavors & Fragrances at CAGE Conf 17 Mar     13:20           AMN Healthcare Services at Sidoti & CompanyForum 17 Mar     13:20        iRobot at Sidoti & CompanyForum 17 Mar     13:30        Courier Annual Shareholders Meeting 17 Mar     13:30         Fairchild Semiconductor International at Bank of America Conf 17 Mar     10:15            Philip Morris International at CAGE Conf 17 Mar     10:35           Joy Global at Bank of America Conf 17 Mar     11:15          Ingredion at CAGE Conf 17 Mar     11:25           Caterpillar at Bank of America Conf 17 Mar                  Aegion at Sidoti & CompanyForum 17 Mar                  Entegris at Sidoti & CompanyForum 17 Mar                  First Interstate BancSystem at Wells Fargo Investor Forum 17 Mar                  HSN at Sidoti & CompanyForum 17 Mar                  J2 Global at Sidoti & CompanyForum 17 Mar                    Micron Tech at Bank of America and Taiwan Stock Exchange Conf 17 Mar                     Plantronics at Sidoti & CompanyForum 17 Mar                     PNM Resources at Barclays Atlanta CFO Corporate Day 17 Mar     12:00        Royal Gold at Morgan Stanley Corporate Access Day 17 Mar                     Schlumberger NV at Cowen Permian Basin Oilfield Tour 17 Mar                     Teradyne at Bank of America and Taiwan Stock Exchange Conf 17 Mar                  Tessera Tech at Bank of America and Taiwan Stock Exchange Conf 17 Mar                    Vivint Solar at Bank of America Conf 17 Mar     12:30           ADT Annual Shareholders Meeting 17 Mar     12:40           Olin at Sidoti & CompanyForum 17 Mar     12:45        Advanced Energy Industries at Bank of America Conf 17 Mar     14:00        Charter Communications Extraordinary Shareholders Meeting 17 Mar     14:00            Neenah Paper at Sidoti & CompanyForum 17 Mar     14:00         Tiger Media Extraordinary Shareholders Meeting 17 Mar     14:15        Angie's List at Bank of America Conf 17 Mar     14:15           Brink's Co at Bank of America Conf 17 Mar     14:40        EMC Group at NYSSA & Raymond James Conf 17 Mar     14:40          Fair Isaac at Sidoti & CompanyForum 17 Mar     15:00           RingCentral at Bank of America Conf 17 Mar     15:20        MTS Systems at Sidoti & CompanyForum 17 Mar     15:20        National Interstate at NYSSA & Raymond James Conf 17 Mar     15:45        Pool at Bank of America Conf 17 Mar     16:20           American Equity Investment at NYSSA & Raymond James Conf 17 Mar     17:00        Banner Extraordinary Shareholders Meeting 17 Mar     17:00           Quiksilver Annual Shareholders Meeting 17 Mar     17:35        MKS Instruments at Bank of America Conf 17 Mar     17:40       Donegal Group at NYSSA & Raymond James Conf 17 Mar     18:00           Era Group at Sidoti & CompanyForum 17 Mar     18:20        Kingstone Companies at NYSSA & Raymond James Conf 17 Mar     18:20          Moog at Bank of America Conf 17 Mar     18:30           Toro Co Annual Shareholders Meeting 17 Mar     19:05         PTC at Bank of America Conf 17 Mar     19:50          Coupons.com Incorporated at Bank of America Conf 17 Mar     08:00           3M Co at Bank of America Conf 17 Mar     20:35           Clearwater Paper at Bank of America Conf 17 Mar     08:50           Eaton Corp. PLC at Bank of America Conf 17 Mar     09:40          Allison Transmission at Bank of America Conf 18 Mar     13:30            Curtiss-Wright at Bank of America Conf 18 Mar     13:30           Olin at Bank of America Conf 18 Mar     00:00        TeleCommunication at Northland Capital Markets 2015 Conf 18 Mar                     Ameren at Barclays Atlanta CFO Corporate Day 18 Mar                     Apollo Global Management LLC at Wells Fargo Forum 18 Mar                    Ares Management LP at Wells Fargo Forum 18 Mar                     Autozone at Evercore/ISI Retail Summit 18 Mar                     BlackRock at Wells Fargo Forum 18 Mar                  CalAmp at Northland Capital Markets Growth Conf 18 Mar                  CBOE at Wells Fargo Forum 18 Mar                   CME Group at Wells Fargo Forum 18 Mar                  Columbus McKinnon at GHS Conf 18 Mar                      Crane Co at GHS Conf 18 Mar                  Denny's at Janney Consumer Executive Summit 18 Mar                     Diebold at Bank of America Conf 18 Mar                  E*TRADE Financial at Wells Fargo Forum 18 Mar                  Exponent at GHS Conf 18 Mar                     Federal Signal at GHS Conf 18 Mar                    GAIN Capital at Wells Fargo Forum 18 Mar                    Global Power Equipment Group at GHS Conf 18 Mar                     Granite Construction at GHS Conf 18 Mar                  Hardinge at GHS Conf 18 Mar                    Inphi at Northland Capital Markets Growth Conf 18 Mar                  J2 Global at Northland Capital Markets Growth Conf 18 Mar                     KCG at Wells Fargo Forum 18 Mar                   Kofax Ltd at Northland Capital Markets Growth Conf 18 Mar                      Legg Mason at Wells Fargo Forum 18 Mar                     Lowe's Companies at Evercore/ISI Retail Summit 18 Mar                      Manning & Napier at Wells Fargo Forum 18 Mar                  Marchex at Northland Capital Markets Growth Conf 18 Mar                  NASDAQ OMX Group at Wells Fargo Forum 18 Mar                     Northwest Natural Gas Co at Williams Capital Seminar 18 Mar                     Oaktree Capital Group LLC at Wells Fargo Forum 18 Mar                     Plantronics at Northland Capital Markets Growth Conf 18 Mar                  Power Solutions at Northland Capital Markets Growth Conf 18 Mar                  Primoris Services at GHS Conf 18 Mar                     Quanta Services at GHS Conf 18 Mar                     Quantum at Northland Capital Markets Growth Conf 18 Mar                     Questar at Williams Capital Group West Coast Utilities Seminar 18 Mar                     Raymond James Financial at Wells Fargo Forum 18 Mar                  Sterling Construction Company at GHS Conf 18 Mar                      Stifel Financial at Wells Fargo Forum 18 Mar                    TD Ameritrade Holding at Wells Fargo Forum 18 Mar                  Tetra Tech at GHS Conf 18 Mar                     Titan International at GHS Conf 18 Mar                     Tyler Technologies at Northland Capital Markets Growth Conf 18 Mar                  Vertex Energy at GHS Conf 18 Mar                  Vitesse Semiconductor at Northland Capital Markets Growth Conf 18 Mar                     Vulcan Materials Co at GHS Conf 18 Mar                     Xcel Energy at Barclays Atlanta CFO Corporate Day 18 Mar     12:30        American Superconductor Extraordinary Shareholders Meeting 18 Mar     12:45        Cimpress NV at Bank of America Conf 18 Mar     14:00         Fifth Street Finance Annual Shareholders Meeting 18 Mar     14:15           Symetra Financial at JPMorgan Conf 18 Mar     15:00             Agilent Technologies Annual Shareholders Meeting 18 Mar     15:00        Monotype Imaging at Bank of America Conf 18 Mar     15:45          LifeLock at Bank of America Conf 18 Mar     17:00        Starbucks Annual Shareholders Meeting 18 Mar     08:15           Tyson Foods at CAGE Conf 18 Mar     21:00           Hewlett-Packard Co Annual Shareholders Meeting 19 Mar     13:05        Advaxis at The Wall Street Investor Conf 19 Mar     13:05        Federated National Holding Co at The Wall Street Investor Conf 19 Mar     13:05           New Jersey Resources at The Wall Street Investor Conf 19 Mar     13:50       Black Ridge Oil & Gas at The Wall Street Investor Conf 19 Mar     00:00        Callidus Software at Northland Capital Markets Growth Conf 19 Mar                    Calix at Stephens 1x1 Conf 19 Mar                     Tyler Technologies at Stephens 1x1 Conf 19 Mar     14:35       Cortex Pharmaceuticals at The Wall Street Investor Conf 19 Mar     14:35        Ur-Energy at The Wall Street Investor Conf 19 Mar     15:20       Midwest Energy Emissions at The Wall Street Investor Conf 19 Mar     16:50         US Geothermal at The Wall Street Investor Conf 19 Mar     17:35        Dixie Group at The Wall Street Investor Conf 19 Mar     17:35        StemCells at The Wall Street Investor Conf 19 Mar     09:30           Mallinckrodt Plc Annual Shareholders Meeting 19 Mar     09:40            General Electric Co at Bank of America Conf 20 Mar     13:00       RestorGenex at Biocentury Future Leaders 20 Mar     13:30        Ardelyx at Biocentury Future Leaders 20 Mar     11:08           Heico Annual Shareholders Meeting 20 Mar     00:00        Callidus Software at Stephens 1x1 Conf 20 Mar     14:00        Alnylam Pharmaceuticals at Biocentury Future Leaders 20 Mar     14:00          C&J Energy Services Extraordinary Shareholders Meeting 20 Mar     14:00        Helomics at Biocentury Future Leaders 20 Mar     15:00        Argos Therapeutics at Biocentury Future Leaders 20 Mar     15:00        Esperion Therapeutics at Biocentury Future Leaders 20 Mar     15:30        Acceleron Pharma at Biocentury Future Leaders 20 Mar     15:30        Aerie Pharmaceuticals at Biocentury Future Leaders 20 Mar     17:30         NeoStem at Biocentury Future Leaders 20 Mar     17:30        Xencor at Biocentury Future Leaders 20 Mar     18:00        Cara Therapeutics at Biocentury Future Leaders 20 Mar     18:00        Paratek Pharmaceuticals at Biocentury Future Leaders 20 Mar     18:30        Medgenics at Biocentury Future Leaders 20 Mar     19:00        Trevena at Biocentury Future Leaders 20 Mar     19:30        Advaxis at Biocentury Future Leaders 20 Mar     20:00        Celator Pharmaceuticals at Biocentury Future Leaders     22 Mar                   Emerald Oil at Howard Weil Energy Conf 22 Mar                   Northern Oil and Gas at Howard Weil Energy Conf 22 Mar                     Schlumberger NV at Howard Weil Energy Conf 22 Mar                  Triangle Petroleum at Howard Weil Energy Conf 23 Mar                     Concho Resources at Howard Weil Energy Conf 23 Mar                      Navios Maritime at Capital Link Forum 23 Mar                     Range Resources at Howard Weil Energy Conf 23 Mar     12:00        Royal Gold at Barclays Metals & Materials Conf 23 Mar                    Scorpio Tankers at Capital Link Forum 23 Mar                  Star Bulk Carriers at Capital Link Forum 23 Mar     18:30          Matson Annual Shareholders Meeting 23 Mar     20:20           Goodrich Petroleum at Howard Weil Energy Conf              FOR ALL AMERICAN HOLIDAYS      FOR AN INDEX OF ALL DIARIES            If you have any questions or comments on the Corporate diary, please e-mail:     diaries@thomsonreuters.com   ",2015-03-17,MNK,"Tue Mar 17, 2015 | 9:32am EDT",DIARY-U.S. MEETINGS/WEEK AHEAD,http://www.reuters.com//article/diary-us-meetings-week-idUSL3N0WI1XE20150317?type=companyNews
26,"  Jordan's Hikma Pharmaceuticals Plc (HIK.L) has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter.Other bidders for the U.S.-based Boehringer unit include Mallinckrodt Plc (MNK.N) and Perrigo Co (PRGO.N), and a decision could be made within weeks for a sale that could fetch as much as 2 billion euros ($2.3 billion), Bloomberg reported. (bloom.bg/1NqCMdX)However, there is a possibility that the company may choose to retain the asset, Bloomberg reported.A spokesman for Perrigo declined to comment. Representatives at Hikma, Boehringer and Mallinckrodt were immediately not available for comment.   In January, Reuters reported that Boehringer, Germany's second largest drug maker, was considering a sale of Roxane to put a stronger focus on the development and sale of new pharmaceuticals.A company spokeswoman at the time said that Boehringer was not a specialist in generics and was therefore considering whether it made more sense for a generics specialist to own Roxane Labs. Roxane's activities include the development and marketing of Boehringer's generic drugs. It also has a production site making both generic drugs and some of Boehringer's patent-protected drugs.Boehringer had sales of 13.3 billion euros in 2014, of which 76 percent was from prescription medicines.  (Reporting by Shivam Srivastava in Bengaluru; Editing by Leslie Adler)",2015-06-29,MNK,"Mon Jun 29, 2015 | 6:44pm EDT","Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt: Bloomberg",http://www.reuters.com//article/us-boehringer-roxane-idUSKCN0P92VK20150629?type=companyNews
27,"  June 29 Jordan's Hikma Pharmaceuticals Plc  has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter.Other bidders for the U.S.-based Boehringer unit include Mallinckrodt Plc and Perrigo Co, and a decision could be made within weeks for a sale that could fetch as much as 2 billion euros ($2.3 billion), Bloomberg reported. (bloom.bg/1NqCMdX)However, there is a possibility that the company may choose to retain the asset, Bloomberg reported. A spokesman for Perrigo declined to comment. Representatives at Hikma, Boehringer and Mallinckrodt were immediately not available for comment.In January, Reuters reported that Boehringer, Germany's second largest drug maker, was considering a sale of Roxane to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman at the time said that Boehringer was not a specialist in generics and was therefore considering whether it made more sense for a generics specialist to own Roxane Labs. Roxane's activities include the development and marketing of Boehringer's generic drugs. It also has a production site making both generic drugs and some of Boehringer's patent-protected drugs.Boehringer had sales of 13.3 billion euros in 2014, of which 76 percent was from prescription medicines.   ($1 = 0.8902 euros)   (Reporting by Shivam Srivastava in Bengaluru; Editing by Leslie Adler)",2015-06-29,MNK,"Mon Jun 29, 2015 | 6:37pm EDT","Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg",http://www.reuters.com//article/boehringer-roxane-idUSL3N0ZF0PR20150629?type=companyNews
28,"  Drugmaker Mallinckrodt Plc (MNK.N) agreed to buy immunotherapy company Therakos Inc in a $1.33 billion deal, its second major acquisition this year to bolster its presence in hospitals.Therakos's flagship system is used to treat symptoms associated with a common form of blood cancer in patients who have been unresponsive to prior treatments.The platform is used by academic medical centers, hospitals and treatment centers in more than 25 countries.Devices based on Therakos's technology are the world's only approved fully integrated systems for extracorporeal photopheresis, or ECP, in which blood is treated with a photosensitizing agent and irradiated with light.Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday.Dublin-based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of blood cancer.Outside the United States, the device is also used to treat Crohn's disease, among other applications.Mallinckrodt's purchase of Therakos from investment firm Gores Group adds to its line of products that cater to surgical pain management and respiratory therapies in neonatal intensive care units.Mallinckrodt, spun off from Covidien Plc in 2013, has relied on acquisitions to fuel growth. Last year, it bought Questcor Pharmaceuticals for about $5.9 billion and Cadence Pharmaceuticals for about $1.3 billion.Mallinckrodt said in March it would buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion. The Ikaria deal gave Mallinckrodt access to INOMAX, the only approved product to treat hypoxic respiratory failure in infants.The Therakos acquisition fits with the INOMAX buy, Mallinckrodt executives said on a call with analysts. Mallinckrodt plans to sell Therakos's devices to hospitals already using INOMAX and expects to generate sales of $500 million or more annually.Mallinckrodt will finance the acquisition with cash and debt.It said it expected the deal to add at least 10 cents per share to adjusted profit in 2016, assuming a close in late fiscal 2015 ending September.Gores Group bought Therakos from Ortho-Clinical Diagnostics Inc, a former subsidiary of Johnson & Johnson (JNJ.N), in 2012. Barclays advised Mallinckrodt on the deal, while Jefferies was Therakos's adviser. Up to Friday's close, Mallinckrodt's shares had risen 47 percent in the past 12 months, outperforming an 8 percent rise in the S&P 500 Index .SPX.(This version of the story corrects to ""blood"" from ""skin"" cancer in second and sixth paragraphs)     (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila, Savio D'Souza and Don Sebastian)",2015-08-10,MNK,"Mon Aug 10, 2015 | 6:34pm EDT",Mallinckrodt buys immunotherapy maker Therakos in $1.33 billion deal,http://www.reuters.com//article/us-therakos-m-a-mallinckrodt-idUSKCN0QF0ZX20150810?type=companyNews
29,"  (Corrects to ""blood"" from ""skin"" cancer in second and sixth paragraphs)* Therakos deal to add at least $0.10/shr to 2016 adj profit* Therakos's device could generate sales of $500 mln a yearAug 10 Drugmaker Mallinckrodt Plc agreed to buy immunotherapy company Therakos Inc in a $1.33 billion deal, its second major acquisition this year to bolster its presence in hospitals.Therakos's flagship system is used to treat symptoms associated with a common form of blood cancer in patients who have been unresponsive to prior treatments.The platform is used by academic medical centers, hospitals and treatment centers in more than 25 countries.Devices based on Therakos's technology are the world's only approved fully integrated systems for extracorporeal photopheresis, or ECP, in which blood is treated with a photosensitizing agent and irradiated with light.Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Dublin-based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of blood cancer.Outside the United States, the device is also used to treat Crohn's disease, among other applications.Mallinckrodt's purchase of Therakos from investment firm Gores Group adds to its line of products that cater to surgical pain management and respiratory therapies in neonatal intensive care units.Mallinckrodt, spun off from Covidien Plc in 2013, has relied on acquisitions to fuel growth. Last year, it bought Questcor Pharmaceuticals for about $5.9 billion and Cadence Pharmaceuticals for about $1.3 billion.Mallinckrodt said in March it would buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion.The Ikaria deal gave Mallinckrodt access to INOMAX, the only approved product to treat hypoxic respiratory failure in infants. The Therakos acquisition fits with the INOMAX buy, Mallinckrodt executives said on a call with analysts.Mallinckrodt plans to sell Therakos's devices to hospitals already using INOMAX and expects to generate sales of $500 million or more annually.Mallinckrodt will finance the acquisition with cash and debt.It said it expected the deal to add at least 10 cents per share to adjusted profit in 2016, assuming a close in late fiscal 2015 ending September.Gores Group bought Therakos from Ortho-Clinical Diagnostics Inc, a former subsidiary of Johnson & Johnson, in 2012.Barclays advised Mallinckrodt on the deal, while Jefferies was Therakos's adviser.Up to Friday's close, Mallinckrodt's shares had risen 47 percent in the past 12 months, outperforming an 8 percent rise in the S&P 500 Index.   (Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila, Savio D'Souza and Don Sebastian)",2015-08-10,MNK,"Mon Aug 10, 2015 | 6:33pm EDT",CORRECTED-UPDATE 4-Mallinckrodt buys immunotherapy maker Therakos in $1.33 bln deal,http://www.reuters.com//article/therakos-ma-mallinckrodt-idUSL3N10L3I820150810?type=companyNews
30,"  Shares of Mallinckrodt Plc closed down 17 percent after short-seller Citron Research called the drugmaker ""a far worse offender of the reimbursement system"" in a tweet.Earlier in October, Citron had accused Canadian drugmaker Valeant Pharmaceuticals International Inc of using specialty pharmacies to inflate revenue.""The market has been so focused on Valeant that they forgot about other platform companies, which are levered and face the same headwinds in reimbursement,"" Citron's Andrew Left said in an email.Shares of Valeant are down more than 40 percent since the short seller published its report on the company on Oct. 21.Specialty pharmacies are designed to handle complex medications such as cancer drugs, which require careful handling, storage and distribution. However, Valeant has used such pharmacies to sell more conventional medicines directly to patients to get past limits on a drug's use imposed by insurers or retail pharmacies.Citron indicated that it would disclose more in a report on Mallinckrodt, but did not say when it would be published. (bit.ly/1ScY0O9)Mallinckrodt, which has a market value of $8.2 billion, makes specialty drugs, medical imaging agents and generic drugs. Hedge funds Paulson & Co Inc and Janus Capital Management LLC are two of Mallinckrodt's biggest shareholders, with a stake of 5.62 percent and 5.43 percent, respectively, according to Thomson Reuters data.    Paulson also has a 2.64 pct stake in Valeant. Mallinckrodt, whose shares hit a near two-year low of $52.01 earlier on Monday, told CNBC that it is fully confident in its business model.(Corrects to fix company name in the headline to Citron, from Citrun) (Reporting by Vidya L Nathan and Ankur Banerjee in Bengaluru; Additional reporting by Davide Scigliuzzo from IFR; Editing by Anil D'Silva and Sriraj Kalluvila)",2015-11-09,MNK,"Mon Nov 9, 2015 | 5:01pm EST","Citron turns spotlight on Mallinckrodt, shares plunge",http://www.reuters.com//article/us-mallinckrodt-stocks-citron-idUSKCN0SY2CT20151109?type=companyNews
31,"  (Corrects to fix company name in the headline to Citron, from Citrun)Nov 9 Shares of Mallinckrodt Plc closed down 17 percent after short-seller Citron Research called the drugmaker ""a far worse offender of the reimbursement system"" in a tweet.Earlier in October, Citron had accused Canadian drugmaker Valeant Pharmaceuticals International Inc  of using specialty pharmacies to inflate revenue.""The market has been so focused on Valeant that they forgot about other platform companies, which are levered and face the same headwinds in reimbursement,"" Citron's Andrew Left said in an email.Shares of Valeant are down more than 40 percent since the short seller published its report on the company on Oct. 21. Specialty pharmacies are designed to handle complex medications such as cancer drugs, which require careful handling, storage and distribution.However, Valeant has used such pharmacies to sell more conventional medicines directly to patients to get past limits on a drug's use imposed by insurers or retail pharmacies. Citron indicated that it would disclose more in a report on Mallinckrodt, but did not say when it would be published. (bit.ly/1ScY0O9)Mallinckrodt, which has a market value of $8.2 billion, makes specialty drugs, medical imaging agents and generic drugs. Hedge funds Paulson & Co Inc and Janus Capital Management LLC are two of Mallinckrodt's biggest shareholders, with a stake of 5.62 percent and 5.43 percent, respectively, according to Thomson Reuters data.Paulson also has a 2.64 pct stake in Valeant.Mallinckrodt, whose shares hit a near two-year low of $52.01 earlier on Monday, told CNBC that it is fully confident in its business model.   (Reporting by Vidya L Nathan and Ankur Banerjee in Bengaluru; Additional reporting by Davide Scigliuzzo from IFR; Editing by Anil D'Silva and Sriraj Kalluvila)",2015-11-09,MNK,"Mon Nov 9, 2015 | 4:59pm EST","REFILE-UPDATE 2-Citron turns spotlight on Mallinckrodt, shares plunge",http://www.reuters.com//article/mallinckrodt-stocks-citron-idUSL3N1345LP20151109?type=companyNews
32,"  Nov 9 Shares of Mallinckrodt Plc fell as much as 26 percent on Monday after short-seller Citron Research called the drugmaker ""a far worse offender of the reimbursement system"" in a tweet.Citron also indicated that it would disclose more in a report. (bit.ly/1ScY0O9)  Shares of Mallinckrodt - which makes specialty drugs, medical imaging agents and generic drugs - were down 15 percent at $59.01 on the New York Stock Exchange.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D'Silva) ",2015-11-09,MNK,"Mon Nov 9, 2015 | 2:27pm EST",Mallinckrodt plunges after Citron tweet,http://www.reuters.com//article/mallinckrodt-stocks-citron-idUSL3N1345L920151109?type=companyNews
33,"  Influential short-seller Citron Research's Andrew Left, who  accused Mallinckrodt Plc (MNK.N) of being an offender of the reimbursement system, told CNBC on Tuesday that he has a short position on the company's stock.Mallinckrodt's stock plunged 26 percent on Monday after Left's tweet on the drugmaker.However, the stock recovered on Tuesday and were up 8.11 percent at $62.71 in late afternoon trading as Left did not lay out specific accusations against the company.Left, in the interview to CNBC, accused Mallinckrodt's Chief Executive Mark Trudeau of misrepresenting the efficacy of the drugmaker's biggest product, Acthar. Acthar, which has been in the U.S. market for the past 65 years, accounted for about 28 percent of Mallinckrodt's latest quarterly revenue of $965.1 million. Mallinckrodt gained rights to Acthar Gel through its acquisition of Questcor Pharmaceuticals Inc for about $5.6 billion in 2014. Trudeau called the short-seller's accusations ""completely false"" in an interview with CNBC.Citron published a scathing report on Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) late October, accusing the Canadian drugmaker of using specialty pharmacies to inflate revenue. Shares plunged 40 percent on the day. ""My short on Valeant has been significantly scaled down from where it was earlier,"" Left told CNBC on Tuesday. (Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva and Sriraj Kalluvila)",2015-11-10,MNK,"Tue Nov 10, 2015 | 3:26pm EST",Citron's Left discloses short position in Mallinckrodt,http://www.reuters.com//article/us-malinckrodt-stocks-citron-idUSKCN0SZ2MD20151110?type=companyNews
34,"  (Adds Mallinckrodt response; updates shares)Nov 10 Influential short-seller Citron Research's Andrew Left, who  accused Mallinckrodt Plc of being an offender of the reimbursement system, told CNBC on Tuesday that he has a short position on the company's stock.Mallinckrodt's stock plunged 26 percent on Monday after Left's tweet on the drugmaker.However, the stock recovered on Tuesday and were up 8.11 percent at $62.71 in late afternoon trading as Left did not lay out specific accusations against the company. Left, in the interview to CNBC, accused Mallinckrodt's Chief Executive Mark Trudeau of misrepresenting the efficacy of the drugmaker's biggest product, Acthar.Acthar, which has been in the U.S. market for the past 65 years, accounted for about 28 percent of Mallinckrodt's latest quarterly revenue of $965.1 million. Mallinckrodt gained rights to Acthar Gel through its acquisition of Questcor Pharmaceuticals Inc for about $5.6 billion in 2014. Trudeau called the short-seller's accusations ""completely false"" in an interview with CNBC.Citron published a scathing report on Valeant Pharmaceuticals International Inc  late October, accusing the Canadian drugmaker of using specialty pharmacies to inflate revenue. Shares plunged 40 percent on the day.""My short on Valeant has been significantly scaled down from where it was earlier,"" Left told CNBC on Tuesday.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva and Sriraj Kalluvila)",2015-11-10,MNK,"Tue Nov 10, 2015 | 3:25pm EST",UPDATE 1-Citron's Left discloses short position in Mallinckrodt,http://www.reuters.com//article/malinckrodt-stocks-citron-idUSL3N13556V20151110?type=companyNews
35,"  Nov 10 Influential short-seller Citron Research's Andrew Left, who  accused Mallinckrodt Plc of being an offender of the reimbursement system, told CNBC on Tuesday that he has a short position on the company's stock.Mallinckrodt's stock plunged 26 percent on Monday after Left's tweet on the drugmaker. However, the stock recovered on Tuesday and gained 6 percent by afternoon as Left did not lay out specific accusations against the company. Citron published a scathing report on Valeant Pharmaceuticals International Inc  late October, accusing the Canadian drugmaker of using specialty pharmacies to inflate revenue. Shares plunged 40 percent on the day. ""My short on Valeant has been significantly scaled down from where it was earlier,"" Left told CNBC on Tuesday.   (Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva)",2015-11-10,MNK,"Tue Nov 10, 2015 | 2:06pm EST",Citron's Left discloses short position in Mallinckrodt,http://www.reuters.com//article/malinckrodt-stocks-citron-idUSL3N13553M20151110?type=companyNews
36,"  Shares of Mallinckrodt Plc (MNK.N) closed down 17 percent after short-seller Citron Research called the drugmaker ""a far worse offender of the reimbursement system"" in a tweet.Earlier in October, Citron had accused Canadian drugmaker Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) of using specialty pharmacies to inflate revenue.""The market has been so focused on Valeant that they forgot about other platform companies, which are levered and face the same headwinds in reimbursement,"" Citron's Andrew Left said in an email.Shares of Valeant are down more than 40 percent since the short seller published its report on the company on Oct. 21.Specialty pharmacies are designed to handle complex medications such as cancer drugs, which require careful handling, storage and distribution. However, Valeant has used such pharmacies to sell more conventional medicines directly to patients to get past limits on a drug's use imposed by insurers or retail pharmacies.Citron indicated that it would disclose more in a report on Mallinckrodt, but did not say when it would be published. (bit.ly/1ScY0O9)Mallinckrodt, which has a market value of $8.2 billion, makes specialty drugs, medical imaging agents and generic drugs. Hedge funds Paulson & Co Inc and Janus Capital Management LLC are two of Mallinckrodt's biggest shareholders, with a stake of 5.62 percent and 5.43 percent, respectively, according to Thomson Reuters data.    Paulson also has a 2.64 pct stake in Valeant. Mallinckrodt, whose shares hit a near two-year low of $52.01 earlier on Monday, told CNBC that it is fully confident in its business model.(Corrects to fix company name in the headline to Citron, from Citrun) (Reporting by Vidya L Nathan and Ankur Banerjee in Bengaluru; Additional reporting by Davide Scigliuzzo from IFR; Editing by Anil D'Silva and Sriraj Kalluvila)",2015-11-10,MNK,"Mon Nov 9, 2015 | 7:16pm EST","Citron turns spotlight on Mallinckrodt, shares plunge",http://www.reuters.com//article/us-mallinckrodt-stocks-citron-idUSKCN0SY2CT20151110?type=companyNews
37,     ,2016-02-03,MNK,"Wed Feb 3, 2016 | 2:49am EST",A,http://www.reuters.com//article/idUSASB0AS9H?type=companyNews
38,  (Corrects Q1 Thomson Reuters I/B/E/S estimate to $1.78 from $1.58 in fifth bullet)Feb 3 Mallinckrodt Plc :  * Reports fiscal 2016 first quarter results  * Q1 adjusted earnings per share $2.09  * Q1 GAAP earnings per share $1.00 from continuing operations  * Q1 sales $914.8 million versus I/B/E/S view $886.6 million  * Q1 earnings per share view $1.78 -- Thomson Reuters I/B/E/S  * Says raises fiscal 2016 adjusted diluted earnings per share guidance  * Raises FY 2016 adjusted earnings per share view to $7.85 to $8.30 versus prior view of $7.70 to $8.20  * Source text for Eikon   * Further company coverage   ,2016-02-03,MNK,"Wed Feb 3, 2016 | 2:48am EST",CORRECTED-BRIEF-Mallinckrodt Q1 adjusted earnings per share $2.09 (Feb 2),http://www.reuters.com//article/mallinckrodt-results-idUSL3N15I2YJ?type=companyNews
39,"  May 3 Mallinckrodt Plc* Mallinckrodt PLC reports fiscal 2016 second quarter results* Q2 adjusted earnings per share $2.01* Q2 GAAP earnings per share $1.07 from continuing operations * Q2 sales $918 million * Sees FY 2016 adjusted earnings per share $8.15 to $8.50* Q2 earnings per share view $1.73, revenue view $871.5 million -- Thomson Reuters I/B/E/S * Raises fiscal 2016 adjusted diluted earnings per share guidance* Fy2016 earnings per share view $8.04 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-03,MNK,"Tue May 3, 2016 | 6:08am EDT",BRIEF-Mallinckrodt PLC reports Q2 adjusted earnings $2.01/shr,http://www.reuters.com//article/idUSASC08M3F?type=companyNews
40,  May 17 Mallinckrodt Plc* Study is expected to take a number of years  * First patient enrolled in mallinckrodt phase 4 trial of h.p. acthar gel for rare cause of nephrotic syndrome  Source text for Eikon:  Further company coverage:    ) ,2016-05-17,MNK,"Tue May 17, 2016 | 4:18pm EDT",BRIEF-Mallinckrodt says first patient enrolled in phase 4 trial of H.P. Acthar gel for rare cause of nephrotic syndrome,http://www.reuters.com//article/idUSASC08Q6U?type=companyNews
41,"  May 19 Mallinckrodt Plc* Mallinckrodt Plc to change fiscal year * Decision will result in a transition period from Oct. 1 to Dec. 30, 2016 * The subsequent first full fiscal year will end on Dec. 29, 2017, with co's current ""4/5/4"" reporting convention remaining same * Approved a change in company's fiscal year end to last Friday in December from last Friday in September  Source text for Eikon:  Further company coverage:",2016-05-18,MNK,"Wed May 18, 2016 | 5:09pm EDT",BRIEF-Mallinckrodt Plc to change fiscal year,http://www.reuters.com//article/idUSFWN18F0P3?type=companyNews
42,  June 9 Mallinckrodt Plc* Mallinckrodt presents new data from 44-week open label extension of company-sponsored H.P. Acthar gel trial in lupus* Findings support advancement of confirmatory trial in lupus population * Mallinckrodt plans to begin company-sponsored study later this year * Patients continuing to receive acthar in open label phase maintained improvements seen in blinded phase * Patients switching to therapy from placebo experienced changes in disease activity measures versus those receiving acthar in double-blind study phase  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780),2016-06-09,MNK,"Thu Jun 9, 2016 | 5:34pm EDT",BRIEF-Mallinckrodt presents new data from 44-week open label extension of H.P. Acthar gel,http://www.reuters.com//article/idUSFWN1910LN?type=companyNews
43,  Aug 2 Mallinckrodt Plc* Q3 adjusted earnings per share $2.20* Q3 gaap earnings per share $1.79 from continuing operations * Q3 sales $971 million * Sees FY 2016 adjusted earnings per share $8.50 to $8.80 * FY2016 earnings per share view $8.28 -- Thomson Reuters I/B/E/S* Now expect results from fiscal year 2016 to come in above high end of previously provided range of $8.15 to $8.50 per share  Source text for Eikon:  Further company coverage:,2016-08-02,MNK,"Tue Aug 2, 2016 | 8:49am EDT",BRIEF-Mallinckrodt Plc reports Q3 adjusted EPS $2.20,http://www.reuters.com//article/idUSASC08ZV0?type=companyNews
44,  Aug 10 Mallinckrodt Plc* Financial terms of transaction were not disclosed  * Mallinckrodt to acquire Stratatech Corporation  Source text for Eikon:  Further company coverage: ,2016-08-10,MNK,"Wed Aug 10, 2016 | 5:49pm EDT",BRIEF-Mallinckrodt Plc to acquire Stratatech Corporation,http://www.reuters.com//article/idUSFWN1AR10G?type=companyNews
45,"  Aug 18 Mallinckrodt PLC* Will build out a new campus for its specialty brands organizations  * Will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy new space in Q1 of 2017  Source text for Eikon:  Further company coverage: ",2016-08-18,MNK,"Thu Aug 18, 2016 | 8:12am EDT",BRIEF-Mallinckrodt will build a new campus for specialty brands organizations,http://www.reuters.com//article/idUSFWN1AZ0DQ?type=companyNews
46,"  Aug 24 Mallinckrodt Plc* Mallinckrodt enters agreement to sell its nuclear imaging business to IBA Molecular for approximately $690 million* Deal for approximately $690 million before tax impacts, including up-front and contingent consideration * Total consideration consists of approximately $574 million of up-front consideration * Price consists of assumption of approximately $39 million of long-term obligations, and approximately $77 million of contingent consideration. * Starting in Q4 of fiscal 2016 (ending September 30, 2016), company will report nuclear imaging business as a discontinued operation  Source text for Eikon:  Further company coverage:",2016-08-24,MNK,"Wed Aug 24, 2016 | 8:12am EDT",BRIEF-Mallinckrodt enters agreement to sell its nuclear imaging business to IBA Molecular,http://www.reuters.com//article/idUSFWN1B50BE?type=companyNews
47,  Aug 25 Mallinckrodt * Receives FDA fast track designation for Synacthen Depot IND Application  Source text for Eikon:  Further company coverage:  ,2016-08-25,MNK,"Thu Aug 25, 2016 | 7:36am EDT",BRIEF-Mallinckrodt receives FDA fast-track designation for Synacthen Depot IND Application,http://www.reuters.com//article/idUSASC09491?type=companyNews
48,  Oct 11 Intellipharmaceutics International Inc* Intellipharmaceutics signs an exclusive license and commercial supply agreement with mallinckrodt* Intellipharmaceutics international inc - Intellipharmaceutics will receive a non-refundable upfront payment of US$3 million in October 2016 * Intellipharmaceutics International Inc - has agreed to manufacture and supply licensed products exclusively for mallinckrodt * Intellipharmaceutics international inc - Mallinckrodt has agreed that Intellipharmaceutics will be its sole supplier of licensed products marketed in u.s * Intellipharmaceutics International- agreement provides for company to have long-term profit sharing arrangement with respect to licensed products  Source text for Eikon:  Further company coverage:,2016-10-11,MNK,"Tue Oct 11, 2016 | 5:52pm EDT",BRIEF-Intellipharmaceutics signs an exclusive license deal with Mallinckrodt,http://www.reuters.com//article/idUSASC09AUQ?type=companyNews
49,"  Oct 21 Mallinckrodt Plc * Says on October 21, Court issued order removing Mallinckrodt's pending litigation with FDA from Court's oral argument calendar  Source text for Eikon:  Further company coverage:  ",2016-10-21,MNK,"Fri Oct 21, 2016 | 5:42pm EDT",BRIEF-Mallinckrodt provides update on co's pending litigation with FDA,http://www.reuters.com//article/idUSFWN1CR0WJ?type=companyNews
50,  Nov 14 Mallinckrodt Plc : * First patient enrolled in mallinckrodt phase 4 trial of h.p. acthar gel for lupus  Source text for Eikon:  Further company coverage:  ,2016-11-14,MNK,"Mon Nov 14, 2016 | 4:57pm EST",BRIEF-First patient enrolled in Mallinckrodt phase 4 trial of H.P. Acthar Gel for lupus,http://www.reuters.com//article/idUSASC09ITC?type=companyNews
51,  Nov 14 Mallinckrodt Plc * First patient enrolled in Mallinckrodt phase 4 trial of H.P. Acthar gel for rheumatoid arthritis  Source text for Eikon:  Further company coverage:  ,2016-11-14,MNK,"Mon Nov 14, 2016 | 7:21am EST",BRIEF-First patient enrolled in Mallinckrodt phase 4 trial of H.P. Acthar gel,http://www.reuters.com//article/idUSASC09IGM?type=companyNews
52,  Nov 18 Mallinckrodt Plc* Mallinckrodt plc - results from clinical pharmacokinetic study examining effect of iv morphine on absorption of orally administered acetaminophen * Mallinckrodt plc - primary data show altered absorption of oral acetaminophen and increased variability when co-administered with iv morphine  * Mallinckrodt plc - secondary data show iv acetaminophen unaffected by co-administered iv morphine  Source text for Eikon:  Further company coverage:,2016-11-18,MNK,"Fri Nov 18, 2016 | 7:47am EST",BRIEF-Mallinckrodt announces results from clinical pharmacokinetic study examining effect of IV Morphine,http://www.reuters.com//article/idUSFWN1DJ0D4?type=companyNews
53,  Nov 21 Mallinckrodt Plc :* Study is expected to begin in first half of 2017 * Says U.S. Fda has granted co's request for a fast track designation for its acthar investigational new drug (IND) application in patients with ALS  * Mallinckrodt will initiate company-sponsored clinical trial of h.p. acthar gel in treatment of amyotropic lateral sclerosis (als)  Source text for Eikon:  Further company coverage:,2016-11-21,MNK,"Mon Nov 21, 2016 | 7:39am EST",BRIEF-Mallinckrodt will initiate company-sponsored clinical trial of h.p. acthar gel in treatment of amyotropic lateral sclerosis,http://www.reuters.com//article/idUSASC09JUY?type=companyNews
54,"  Nov 29 Mallinckrodt Plc :* Q4 gaap earnings per share $1.01 from continuing operations* Mallinckrodt plc reports fiscal 2016 fourth quarter and full-year results * Q4 sales $887.2 million * Q4 adjusted earnings per share $2.04 from continuing operations * Q4 earnings per share view $1.89, revenue view $838.1 million -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-11-29,MNK,"Tue Nov 29, 2016 | 6:15am EST",BRIEF-Mallinckrodt Plc reports 2016 fourth quarter results,http://www.reuters.com//article/idUSASC09KUF?type=companyNews
